Document:AXA/2025/FY/Earnings presentation: Difference between revisions
doc_archive: publish snjra2xp9r (original transcript) (.md link) |
doc_archive: publish snjra2xp9r (original transcript) |
||
| Line 11: | Line 11: | ||
| source_url = https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
| source_url = https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
| wide = yes |
| wide = yes |
||
| original_md = |
| original_md = <!-- ARCHIVE_MD_LINK_HERE --> |
||
| docling_file = |
| docling_file = <!-- ARCHIVE_DOCLING_LINK_HERE --> |
||
| article = AXA/2025/FY/Earnings presentation |
| article = AXA/2025/FY/Earnings presentation |
||
| doc_id = snjra2xp9r |
| doc_id = snjra2xp9r |
||
| Line 20: | Line 20: | ||
--- |
--- |
||
title: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
title: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
source_file: |
source_file: tmpbnfh9bao.pdf |
||
source_url: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
source_url: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
doc_type: slides |
doc_type: slides |
||
pages: 49 |
pages: 49 |
||
tables: |
tables: 51 |
||
converter: anchor_injection/1 |
converter: anchor_injection/1 |
||
tier: |
tier: slides |
||
parsed_at: '2026-07- |
parsed_at: '2026-07-22T13:34:39Z' |
||
scanned_pages: [] |
scanned_pages: [] |
||
residue: |
|||
- '- February 26, 2026' |
|||
--- |
--- |
||
ORIGINAL_FRONTMATTER --> |
ORIGINAL_FRONTMATTER --> |
||
{{pdf page|1|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|1|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Full Year 2025 Earnings Presentation |
=== Full Year 2025 Earnings Presentation === |
||
{{pdf page|2|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|2|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES === |
|||
=== Full Year 2025 Earnings === |
|||
* Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information. Forward-looking statements are generally identified by words and expressions such as "expects", "anticipates", "may", "plan," "target" or any variations or similar terminology of these words and expressions, or conditional verbs such as, without limitations, "would" and "could". In particular, the statements in this presentation regarding expected underlying earnings per share ("UEPS") growth for 2026 are forward-looking statements to provide one-off guidance in the context of the last year of the Group's current strategic plan. These statements in this presentation are based on Management's current views and intentions and are subject to change. Undue reliance should not be placed on forward-looking statements because, by their nature, they are subject to known and unknown risks and uncertainties, many of which are outside AXA's control, and can be affected by other factors that could cause AXA's actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements. Each forward-looking statement speaks only at the date of this presentation. Please refer to Part 5 - "Risk Factors and Risk Management" of AXA's Universal Registration Document for the year ended December 31, 2024 (the "2024 Universal Registration Document") for a description of certain important factors, risks and uncertainties that may affect AXA's business and/or results of operations. AXA specifically disclaims and undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations. |
|||
* GIE_AXA_Internal 2 Full Year 2025 Earnings |
|||
* In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures ("APMs"), used by Management in analyzing AXA's operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding AXA's results. These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group's consolidated financial statements and related notes prepared in accordance with IFRS. "Underlying earnings", UEPS ("underlying earnings per share"), "underlying return on equity", "combined ratio" and "debt gearing" are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ("AXA's 2025 Activity Report"), on the pages indicated under the heading "USE OF NON-GAAP AND ALTERNATIVE PERFORMANCE MEASURES". For further information on the above-mentioned and other non-GAAP financial measures used in this presentation, see the Glossary in AXA's 2025 Activity Report. |
|||
* IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES |
|||
* AXA's Activity Report as of December 31, 2025 is available on the AXA Group website (www.axa.com). |
|||
* Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information. Forward-looking statements are generally identified by words and expressions such as “expects”, “anticipates”, “may”, “plan,” “target” or any variations or similar terminology of these words and expressions, or conditional verbs such as, without limitations, “would” and “could”. In particular, the statements in this presentation regarding expected underlying earnings per share (“UEPS”) growth for 2026 are forward-looking statements to provide one-off guidance in the context of the last year of the Group’s current strategic plan. These statements in this presentation are based on Management’s current views and intentions and are subject to change. Undue reliance should not be placed on forward-looking statements because, by their nature, they are subject to known and unknown risks and uncertainties, many of which are outside AXA’s control, and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements. Each forward-looking statement speaks only at the date of this presentation. Please refer to Part 5 - “Risk Factors and Risk Management” of AXA’s Universal Registration Document for the year ended December 31, 2024 (the “2024 Universal Registration Document”) for a description of certain important factors, risks and uncertainties that may affect AXA’s business and/or results of operations. AXA specifically disclaims and undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations. |
|||
* AXA's consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure by AXA's statutory auditors. |
|||
* In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures (“APMs”), used by Management in analyzing AXA’s operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding AXA’s results. These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group’s consolidated financial statements and related notes prepared in accordance with IFRS. “Underlying earnings”, UEPS (“underlying earnings per share”), “underlying return on equity”, “combined ratio” and “debt gearing” are APMs as defined in ESMA’s guidelines and the AMF’s related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 (“AXA’s 2025 Activity Report”), on the pages indicated under the heading “USE OF NON-GAAP AND ALTERNATIVE PERFORMANCE MEASURES”. For further information on the above-mentioned and other non-GAAP financial measures used in this presentation, see the Glossary in AXA’s 2025 Activity Report. |
|||
* AXA’s Activity Report as of December 31, 2025 is available on the AXA Group website (www.axa.com). |
|||
* AXA’s consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure by AXA’s statutory auditors. |
|||
{{pdf page|3|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|3|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== |
=== Table of contents === |
||
* 1. FY25 Highlights p.04 |
* 1. FY25 Highlights p.04 |
||
* Thomas Buberl, Group CEO |
* Thomas Buberl, Group CEO |
||
| Line 59: | Line 59: | ||
{{pdf page|5|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|5|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Full Year 2025 – Excellent performance === |
=== Full Year 2025 – Excellent performance === |
||
* +6% Revenues vs. FY24 |
* +6% Revenues vs. FY24 |
||
* +8% |
* +8% Underlying EPS vs. FY24 |
||
* 16% ROE FY25 |
|||
* |
* 224% Solvency II ratio FY25 |
||
* Delivering value for shareholders: +8% DPS{{fn ref|1|2=Based on the dividend proposed by AXA’s Board of Directors on February 25, 2026 and subject to approval by the Shareholders’ Annual General Meeting to be held on April 30, 2026.}} growth and €1.25bn annual share buy back{{fn ref|2|2=Following AXA’s Board of Directors’ approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
|||
* 224% Solvency II ratio — FY25 |
|||
* Delivering value for shareholders +8% DPS{{fn ref|1|2=Based on the dividend proposed by AXA's Board of Directors on February 25, 2026 and subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.}} growth and €1.25bn annual share buy back{{fn ref|2|2=Following AXA's Board of Directors' approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
|||
* Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026 |
* Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026 |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Based on the dividend proposed by |
{{fn note|1=1|2=Based on the dividend proposed by AXA’s Board of Directors on February 25, 2026 and subject to approval by the Shareholders’ Annual General Meeting to be held on April 30, 2026.}} |
||
{{fn note|1=2|2=Following |
{{fn note|1=2|2=Following AXA’s Board of Directors’ approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
||
</div> |
</div> |
||
| Line 81: | Line 76: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t1" class="wikitable fintable" |
{| id="t1" class="wikitable fintable" |
||
|+ Underlying earnings (In Euro billion) |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | Underlying earnings |
| style="text-align:left" | Underlying earnings |
||
| style="text-align:right" | 8.1 |
| style="text-align:right" | 8.1 |
||
| style="text-align:right" | 8.4 |
| style="text-align:right" | 8.4 |
||
| style="text-align:right" | +6% |
|||
|- |
|||
| style="text-align:left" | Underlying earnings excluding AXA IM |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | +9% |
|||
|} |
|} |
||
</div> |
</div> |
||
+6% ( +9% excluding AXA IM) |
|||
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) |
|||
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency |
|||
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) |
|||
* Scaling the business: Continued investments in growth and technology |
|||
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency |
|||
* Consistent earnings growth while enhancing reserve prudence |
|||
* Scaling the business: Continued investments in growth and technology |
|||
 Consistent earnings growth while enhancing reserve prudence |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 115: | Line 105: | ||
* Protection gaps and emerging corporate risks |
* Protection gaps and emerging corporate risks |
||
* Demographics driving demand for private retirement and healthcare |
* Demographics driving demand for private retirement and healthcare |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t2" class="wikitable fintable" |
{| id="t2" class="wikitable fintable" |
||
|+ FY25 gross written premium split |
|+ Pie chart represents FY25 gross written premium split excluding AXA IM and holdings. |
||
|- |
|- |
||
! style="text-align:left" | Segment |
! style="text-align:left" | Segment |
||
| Line 141: | Line 130: | ||
|} |
|} |
||
</div> |
</div> |
||
<!-- furniture --> |
|||
<!-- furniture --> |
|||
==== Our right to win ==== |
==== Our right to win ==== |
||
* Leading brand & high customer NPS |
* Leading brand & high customer NPS |
||
* Strong and diversified distribution |
* Strong and diversified distribution |
||
* Technical expertise to price & underwrite risks |
* Technical expertise to price & underwrite risks |
||
* Scale offering cost advantage |
* Scale offering cost advantage |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Pie chart represents FY25 gross written premium split excluding AXA IM and holdings.}} |
|||
</div> |
|||
{{pdf page|8|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|8|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Laying the foundation for the next plan === |
=== Laying the foundation for the next plan === |
||
* Clear tech and AI roadmap |
* Clear tech and AI roadmap |
||
* Driving efficiency |
* Driving efficiency |
||
| Line 173: | Line 153: | ||
{{pdf page|10|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|10|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
<!-- furniture --> |
|||
=== Strong delivery across our businesses === |
=== Strong delivery across our businesses === |
||
| Line 180: | Line 158: | ||
{| id="t3" class="wikitable" |
{| id="t3" class="wikitable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Segment |
||
! style="text-align:right" | Gross written premiums |
! style="text-align:right" | Gross written premiums |
||
! style="text-align:right" | Underlying earnings |
! style="text-align:right" | Underlying earnings |
||
|- |
|- |
||
| style="text-align:left" | France |
| style="text-align:left" | France<br/>(27% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}}) |
||
| style="text-align:right" | +6% |
| style="text-align:right" | +6%<br/>to €31bn |
||
| style="text-align:right" | +7% |
| style="text-align:right" | +7%<br/>to €2.2bn |
||
|- |
|- |
||
| style="text-align:left" | Europe |
| style="text-align:left" | Europe<br/>(38% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}}) |
||
| style="text-align:right" | +6% |
| style="text-align:right" | +6%<br/>to €43bn |
||
| style="text-align:right" | +9% |
| style="text-align:right" | +9%<br/>to €3.5bn |
||
|- |
|- |
||
| style="text-align:left" | AXA XL |
| style="text-align:left" | AXA XL<br/>(17% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}}) |
||
| style="text-align:right" | +4% |
| style="text-align:right" | +4%<br/>to €19bn |
||
| style="text-align:right" | +9% |
| style="text-align:right" | +9%<br/>to €1.9bn |
||
|- |
|- |
||
| style="text-align:left" | Asia, Africa & EME-LATAM |
| style="text-align:left" | Asia, Africa & EME-LATAM<br/>(18% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}}) |
||
| style="text-align:right" | +13% |
| style="text-align:right" | +13%<br/>to €20bn |
||
| style="text-align:right" | +6% |
| style="text-align:right" | +6%<br/>to €1.5bn |
||
|} |
|} |
||
</div> |
</div> |
||
| Line 209: | Line 187: | ||
=== P&C – Strong margins, confidence in sustaining growth === |
=== P&C – Strong margins, confidence in sustaining growth === |
||
* GWP €58bn: Retail, SME & Mid-market, AXA XL{{fn ref|1|2=Includes AXA XL Re premiums of €2.6bn.}} (Large & Specialty) |
|||
* €58bn GWP |
|||
* 2025 / Beyond 2025: |
|||
* GWP mix: Retail, SME & Mid-market, AXA XL{{fn ref|1|2=Includes AXA XL Re premiums of €2.6bn.}} (Large & Specialty) — shares not printed |
|||
* Retail and SME & Mid-market: Growing volumes while expanding margins (2025) | Investing to improve customer retention & expanding distribution footprint (Beyond 2025) |
|||
* AXA XL (Large & Specialty): Profitable growth with stable margins (2025) | Capitalizing on attractive growth opportunities and continued cycle management (Beyond 2025) |
|||
* Underlying earnings +9%{{fn ref|2|2=Change FY25 vs. FY24 at constant FX.}} to €5.9bn |
* Underlying earnings +9%{{fn ref|2|2=Change FY25 vs. FY24 at constant FX.}} to €5.9bn |
||
* Continued progress on efficiency | Higher investment income | Data & AI to further enhance customer experience & technical excellence |
|||
<div style="overflow-x:auto"> |
|||
{| id="t4" class="wikitable" |
|||
|+ 2025 and Beyond 2025 outlook |
|||
|- |
|||
! style="text-align:left" | |
|||
! style="text-align:left" | 2025 |
|||
! style="text-align:left" | Beyond 2025 |
|||
|- |
|||
| style="text-align:left" | Retail and SME & Mid-market |
|||
| style="text-align:left" | Growing volumes while expanding margins |
|||
| style="text-align:left" | Investing to improve customer retention & expanding distribution footprint |
|||
|- |
|||
| style="text-align:left" | AXA XL (Large & Specialty) |
|||
| style="text-align:left" | Profitable growth with stable margins |
|||
| style="text-align:left" | Capitalizing on attractive growth opportunities and continued cycle management |
|||
|} |
|||
</div> |
|||
* Continued progress on efficiency |
|||
* Higher investment income |
|||
* Data & AI to further enhance customer experience & technical excellence |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 244: | Line 204: | ||
{{pdf page|12|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|12|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== L&H – Good momentum, well positioned to capture growth opportunities === |
=== L&H – Good momentum, well positioned to capture growth opportunities === |
||
* GWP: €57bn (Short-term, Long-term — shares not printed) |
|||
2025 | Beyond 2025 |
|||
<div style="overflow-x:auto"> |
|||
{| id="t5" class="wikitable" |
|||
|+ GWP |
|||
|- |
|||
| style="text-align:left" | Short-term |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Long-term |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Total GWP |
|||
| style="text-align:right" | €57bn |
|||
|} |
|||
</div> |
|||
* Underlying earnings +7%{{fn ref|1|2=1. Change FY25 vs. FY24 at constant FX.}} to €3.5bn |
|||
==== 2025 Beyond 2025 ==== |
|||
* Long-term business |
* Long-term business |
||
* Accelerating net flows in Savings at attractive margins |
* Accelerating net flows in Savings at attractive margins |
||
* Capturing savings & retirement opportunity, sourcing best asset management products for our customers |
* Capturing savings & retirement opportunity, sourcing best asset management products for our customers |
||
* Short-term business |
* Short-term business |
||
* Growing technical results while absorbing Mexico VAT impact |
* Growing technical results while absorbing Mexico VAT impact |
||
* Capitalizing on demand for health & protection while further improving our margins |
* Capitalizing on demand for health & protection while further improving our margins |
||
* Underlying earnings +7%{{fn ref|1|2=Change FY25 vs. FY24 at constant FX.}} to €3.5bn |
|||
* Focus on cost reduction |
* Focus on cost reduction |
||
* Increasing penetration of Protection riders in Savings offerings |
* Increasing penetration of Protection riders in Savings offerings |
||
* Leveraging AI to reduce claims leakage & improve customer outcomes in Health |
* Leveraging AI to reduce claims leakage & improve customer outcomes in Health |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2= |
{{fn note|1=1|2=Change FY25 vs. FY24 at constant FX.}} |
||
</div> |
</div> |
||
| Line 286: | Line 232: | ||
{{pdf page|14|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|14|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – Continued disciplined growth === |
=== P&C – Continued disciplined growth === |
||
* In Euro billion |
|||
==== GWP & Other Revenues ==== |
==== GWP & Other Revenues ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t4" class="wikitable fintable" |
||
|+ GWP & Other Revenues |
|+ GWP & Other Revenues |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 333: | Line 277: | ||
* Continued pricing momentum and volume growth in Mid-market and SME |
* Continued pricing momentum and volume growth in Mid-market and SME |
||
* Growing in lines of business with attractive margins while |
* Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance |
||
* Growth supported by alternative capital |
* Growth supported by alternative capital |
||
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) |
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=none|2=Change at constant scope and FX.}} |
|||
{{fn note|1=1|2=Price effect.}} |
{{fn note|1=1|2=Price effect.}} |
||
{{fn note|1=2|2=Includes exposure adjustments and mix & other effects.}} |
{{fn note|1=2|2=Includes exposure adjustments and mix & other effects.}} |
||
| Line 348: | Line 293: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t5" class="wikitable fintable" |
||
|+ Combined ratio |
|+ Combined ratio |
||
|- |
|- |
||
| Line 354: | Line 299: | ||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|||
| style="text-align:left" | Combined ratio |
|||
| style="text-align:right" | 91.0% |
|||
| style="text-align:right" | 90.6% |
|||
|- |
|- |
||
| style="text-align:left" | Undiscounted CY loss ratio (ex Nat Cat) |
| style="text-align:left" | Undiscounted CY loss ratio (ex Nat Cat) |
||
| Line 378: | Line 319: | ||
| style="text-align:right" | -3.6% |
| style="text-align:right" | -3.6% |
||
| style="text-align:right" | -3.5% |
| style="text-align:right" | -3.5% |
||
|- |
|||
| style="text-align:left" | |
|||
| style="text-align:right" | 91.0% |
|||
| style="text-align:right" | 90.6% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 383: | Line 328: | ||
* Better undiscounted current year loss ratio excluding Nat Cat from: |
* Better undiscounted current year loss ratio excluding Nat Cat from: |
||
* Margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment |
* Margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment |
||
* Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management |
|||
* Improvement in expense ratio reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology |
|||
* Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management |
|||
* Improvement in expense ratio reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology |
|||
* Nat Cat charges below normalized load |
* Nat Cat charges below normalized load |
||
* Lower reliance on prior year reserve development |
* Lower reliance on prior year reserve development |
||
* Taking advantage of a good year to enhance reserve prudence |
* Taking advantage of a good year to enhance reserve prudence |
||
| Line 400: | Line 340: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t6" class="wikitable fintable" |
||
|+ Underlying Earnings |
|+ Underlying Earnings |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | In Euro million |
||
|- |
|- |
||
| style="text-align:left" | FY24 |
| style="text-align:left" | FY24 |
||
| style="text-align:right" | 5,510 |
| style="text-align:right" | 5,510 |
||
|- |
|- |
||
| style="text-align:left" | Volume growth |
| style="text-align:left" | Volume growth |
||
| style="text-align:right" | +292 |
| style="text-align:right" | +292 |
||
|- |
|- |
||
| Line 415: | Line 355: | ||
| style="text-align:right" | +189 |
| style="text-align:right" | +189 |
||
|- |
|- |
||
| style="text-align:left" | Investment income |
| style="text-align:left" | Investment income |
||
| style="text-align:right" | +435 |
| style="text-align:right" | +435 |
||
|- |
|- |
||
| style="text-align:left" | Insurance finance expenses |
| style="text-align:left" | Insurance finance expenses |
||
| style="text-align:right" | -235 |
| style="text-align:right" | -235 |
||
|- |
|- |
||
| Line 432: | Line 372: | ||
</div> |
</div> |
||
+9% |
|||
* Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence |
|||
* Increase in investment income reflecting higher volumes and better reinvestment yields on fixed income assets |
|||
* Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence |
|||
* Increase in investment income reflecting higher volumes and better reinvestment yields on fixed income assets |
|||
* Higher unwind of discount of claims reserves, in line with guidance |
* Higher unwind of discount of claims reserves, in line with guidance |
||
* Unfavorable forex impact notably due to USD depreciation vs. EUR |
|||
Change at constant FX. |
|||
* Unfavorable forex impact notably due to USD depreciation vs. EUR |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Underwriting result includes expenses.}} |
{{fn note|1=1|2=Underwriting result includes expenses.}} |
||
</div> |
</div> |
||
Full Year 2025 Earnings |
|||
{{pdf page|17|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|17|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 450: | Line 390: | ||
* In Euro billion |
* In Euro billion |
||
==== Life GWP & Other Revenues ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t7" class="wikitable fintable" |
||
|+ Life GWP & Other Revenues |
|+ Life GWP & Other Revenues |
||
|- |
|- |
||
| Line 458: | Line 400: | ||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | Total |
| style="text-align:left" | Total |
||
| Line 486: | Line 428: | ||
|} |
|} |
||
</div> |
</div> |
||
==== Health GWP & Other Revenues ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t8" class="wikitable fintable" |
||
|+ Health GWP & Other Revenues |
|+ Health GWP & Other Revenues |
||
|- |
|- |
||
| Line 494: | Line 438: | ||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | Total |
| style="text-align:left" | Total |
||
| Line 512: | Line 456: | ||
|} |
|} |
||
</div> |
</div> |
||
==== Net flows: €+5.4bn ==== |
|||
* vs. €+1.5bn in FY24 |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t9" class="wikitable fintable" |
||
|+ Net flows: €+5.4bn |
|+ Net flows: €+5.4bn |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | €bn |
||
|- |
|- |
||
| style="text-align:left" | Protection |
| style="text-align:left" | Protection |
||
| Line 537: | Line 485: | ||
</div> |
</div> |
||
* o/w FY25 Employee Benefits{{fn ref|1|2=Including both short-term and long-term Employee Benefits GWP and other revenues.}} |
* o/w FY25 Employee Benefits{{fn ref|1|2=Including both short-term and long-term Employee Benefits GWP and other revenues.}} Euro 12.9 billion (+4% vs. FY24) |
||
* Euro 12.9 billion (+4% vs. FY24) Change at constant scope and FX. |
|||
* Change at constant scope and FX. |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 547: | Line 496: | ||
=== Life & Health – Strong volume growth in Savings and Protection impacted by higher interest rates on discounting === |
=== Life & Health – Strong volume growth in Savings and Protection impacted by higher interest rates on discounting === |
||
PVEP |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t10" class="wikitable fintable" |
||
|+ PVEP |
|+ PVEP |
||
|- |
|- |
||
| Line 554: | Line 504: | ||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | Protection & Health |
| style="text-align:left" | Protection & Health |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 31.4 |
| style="text-align:right" | 31.4 |
||
| style="text-align:right" | -4% |
|||
|- |
|- |
||
| style="text-align:left" | Unit-Linked |
| style="text-align:left" | Unit-Linked |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 8.5 |
| style="text-align:right" | 8.5 |
||
| style="text-align:right" | +18% |
|||
|- |
|- |
||
| style="text-align:left" | Capital-light G/A |
| style="text-align:left" | Capital-light G/A |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 7.8 |
| style="text-align:right" | 7.8 |
||
| style="text-align:right" | -10% |
|||
|- |
|- |
||
| style="text-align:left" | Traditional G/A |
| style="text-align:left" | Traditional G/A |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 1.7 |
| style="text-align:right" | 1.7 |
||
| style="text-align:right" | -10% |
|||
|- |
|- |
||
| style="text-align:left" | Total |
| style="text-align:left" | Total |
||
| style="text-align:right" | 50.9 |
| style="text-align:right" | 50.9 |
||
| style="text-align:right" | 49.4 |
| style="text-align:right" | 49.4 |
||
| style="text-align:right" | -2% |
|||
|- |
|||
| style="text-align:left" | Change |
|||
| colspan="2" style="text-align:right" | -2% |
|||
|- |
|||
| style="text-align:left" | Protection & Health change |
|||
| colspan="2" style="text-align:right" | -4% |
|||
|- |
|||
| style="text-align:left" | Unit-Linked change |
|||
| colspan="2" style="text-align:right" | +18% |
|||
|- |
|||
| style="text-align:left" | Capital-light G/A change |
|||
| colspan="2" style="text-align:right" | -10% |
|||
|- |
|||
| style="text-align:left" | Traditional G/A change |
|||
| colspan="2" style="text-align:right" | -10% |
|||
|} |
|} |
||
</div> |
</div> |
||
NB CSM (pre-tax) |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t11" class="wikitable fintable" |
||
|+ NB CSM (pre-tax) |
|+ NB CSM (pre-tax) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | NB CSM |
||
| style="text-align:right" | 2.2 |
| style="text-align:right" | 2.2 |
||
| style="text-align:right" | 2.2 |
|||
|- |
|||
| |
| style="text-align:right" | +3% |
||
|} |
|} |
||
</div> |
</div> |
||
NBV (post-tax) |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t12" class="wikitable fintable" |
||
|+ NBV (post-tax) |
|+ NBV (post-tax) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | NBV |
||
| style="text-align:right" | 2.3 |
|||
| style="text-align:right" | 2.2 |
| style="text-align:right" | 2.2 |
||
| style="text-align:right" | stable |
|||
|} |
|||
</div> |
|||
NBV margin |
|||
<div style="overflow-x:auto"> |
|||
{| id="t13" class="wikitable fintable" |
|||
|+ NBV margin |
|||
|- |
|- |
||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|- |
||
| style="text-align:left" | NBV margin |
| style="text-align:left" | NBV margin |
||
| style="text-align:right" | 4.4% |
|||
| style="text-align:right" | 4.5% |
| style="text-align:right" | 4.5% |
||
|} |
|} |
||
| Line 624: | Line 583: | ||
* PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes |
* PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes |
||
* NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits |
* NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits |
||
* NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France |
* NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France |
||
Change at constant scope and FX. |
|||
{{pdf page|19|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|19|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Life & Health – Growth in new business driving Normalized CSM growth === |
=== Life & Health – Growth in new business driving Normalized CSM growth === |
||
* In Euro billion |
|||
==== Contractual Service Margin rollforward ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t14" class="wikitable fintable" |
||
|+ Contractual Service Margin rollforward |
|+ Contractual Service Margin rollforward <br/> Normalized CSM growth +2% |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! style="text-align:right" | |
! class="col-s" style="text-align:right" | Value |
||
! style="text-align: |
! class="col-s" style="text-align:right" | o/w Life |
||
! style="text-align:right" | |
! class="col-s" style="text-align:right" | o/w Health |
||
! style="text-align:right" | Economic variance |
|||
! style="text-align:right" | Operating variance |
|||
! style="text-align:right" | Affiliates, FX & other |
|||
! style="text-align:right" | FY25 |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | FY24 |
||
| style="text-align:right" | 33.6 |
|||
| style="text-align:right" | 25.8 |
|||
| style="text-align:right" | 7.7 |
|||
|- |
|||
| style="text-align:left" | New business CSM |
|||
| style="text-align:right" | +2.2 |
| style="text-align:right" | +2.2 |
||
| style="text-align: |
| style="text-align:right" | |
||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Underlying return on in-force |
|||
| style="text-align:right" | +1.3 |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | CSM release |
|||
| style="text-align:right" | -3.0 |
| style="text-align:right" | -3.0 |
||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Economic variance |
|||
| style="text-align:right" | +0.6 |
| style="text-align:right" | +0.6 |
||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Operating variance |
|||
| style="text-align:right" | -0.3 |
| style="text-align:right" | -0.3 |
||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Affiliates, FX & other |
|||
| style="text-align:right" | -1.4 |
| style="text-align:right" | -1.4 |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
|||
|- |
|- |
||
| |
| style="text-align:left" | FY25 |
||
| style="text-align:right" | 33.0 |
|||
| style="text-align:right" | 25.4 |
|||
| style="text-align:right" | 7.6 |
|||
|} |
|} |
||
</div> |
</div> |
||
* Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates |
|||
* o/w Life: 25.8 (FY24) → 25.4 (FY25) |
|||
* Economic variance reflecting government spreads tightening and positive equity market returns |
|||
* Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland |
|||
* o/w Health: 7.7 (FY24) → 7.6 (FY25) |
|||
* Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates |
|||
* Economic variance reflecting government spreads tightening and positive equity market returns |
|||
* Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland |
|||
* FX impact mainly from JPY and HKD depreciation |
* FX impact mainly from JPY and HKD depreciation |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Change at constant scope and FX.}} |
{{fn note|1=1|2=Change at constant scope and FX.}} |
||
| Line 685: | Line 655: | ||
In Euro million |
In Euro million |
||
==== Underlying Earnings |
==== Underlying Earnings ==== |
||
+7% |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t15" class="wikitable fintable" |
||
|+ Underlying Earnings |
|+ Underlying Earnings |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
| style="text-align:right" | 3,323 |
|||
|- |
|- |
||
| style="text-align:left" | Short-term technical margin |
| style="text-align:left" | Short-term technical margin |
||
| style="text-align:right" | 415 |
|||
| style="text-align:right" | +60 |
| style="text-align:right" | +60 |
||
| style="text-align:right" | 479 |
|||
|- |
|- |
||
| style="text-align:left" | Long-term result incl. CSM release |
| style="text-align:left" | Long-term result incl. CSM release |
||
| style="text-align:right" | 2,680 |
|||
| style="text-align:right" | +156 |
| style="text-align:right" | +156 |
||
| style="text-align:right" | 2,804 |
|||
|- |
|- |
||
| style="text-align:left" | Financial result |
| style="text-align:left" | Financial result |
||
| style="text-align:right" | 975 |
|||
| style="text-align:right" | -11 |
| style="text-align:right" | -11 |
||
| style="text-align:right" | 946 |
|||
|- |
|- |
||
| style="text-align:left" | Tax |
| style="text-align:left" | Tax & others |
||
| style="text-align:right" | -748 |
|||
| style="text-align:right" | -27 |
| style="text-align:right" | -27 |
||
| style="text-align:right" | -728 |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying Earnings |
||
| style="text-align:right" | 3,323 |
|||
| style="text-align:right" | +7% |
|||
| style="text-align:right" | 3,501 |
| style="text-align:right" | 3,501 |
||
|} |
|} |
||
</div> |
</div> |
||
Change at constant FX. |
|||
==== in billions ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t16" class="wikitable fintable" |
||
|+ in billions |
|||
|+ FY24 vs FY25 Underlying Earnings breakdown (In Euro million) |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-m" style="text-align:right" | |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | o/w Life |
||
| style="text-align:right" | |
| style="text-align:right" | 2.6 |
||
| style="text-align:right" | |
| style="text-align:right" | 2.7 |
||
| style="text-align:right" | +4% vs. FY24 |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | o/w Health |
||
| style="text-align:right" | |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | |
| style="text-align:right" | 0.8 |
||
| style="text-align:right" | +17% vs. FY24 |
|||
|- |
|||
| style="text-align:left" | Financial result |
|||
| style="text-align:right" | 975 |
|||
| style="text-align:right" | 946 |
|||
|- |
|||
| style="text-align:left" | Tax & others |
|||
| style="text-align:right" | -748 |
|||
| style="text-align:right" | -728 |
|||
|} |
|} |
||
</div> |
</div> |
||
* o/w Life: 2.6 → 2.7 in billions — +4% vs. FY24 |
|||
* o/w Health: 0.7 → 0.8 in billions — +17% vs. FY24 |
|||
* Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn) |
* Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn) |
||
* Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins |
* Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Change at constant FX.}} |
|||
</div> |
|||
{{pdf page|21|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|21|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Growth in net income reflecting higher earnings & the gain from the sale of AXA IM === |
=== Growth in net income reflecting higher earnings & the gain from the sale of AXA IM === |
||
* In Euro billion |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t17" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col- |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col- |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col- |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | Property & Casualty |
| style="text-align:left" | Property & Casualty |
||
| Line 782: | Line 755: | ||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying earnings |
||
| style="text-align:right" | |
| style="text-align:right" | 8.1 |
||
| style="text-align:right" | |
| style="text-align:right" | 8.4 |
||
| style="text-align:right" | |
| style="text-align:right" | +6% |
||
|- |
|- |
||
| style="text-align:left" | Non-financial flows |
| style="text-align:left" | Non-financial flows |
||
| Line 792: | Line 765: | ||
| style="text-align:right" | |
| style="text-align:right" | |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | o/w capital gains from AXA IM disposal |
||
| style="text-align:right" | - |
| style="text-align:right" | - |
||
| style="text-align:right" | +2.2 |
| style="text-align:right" | +2.2 |
||
| Line 802: | Line 775: | ||
| style="text-align:right" | |
| style="text-align:right" | |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Net income |
||
| style="text-align:right" | |
| style="text-align:right" | 7.9 |
||
| style="text-align:right" | |
| style="text-align:right" | 9.8 |
||
| style="text-align:right" | |
| style="text-align:right" | +26% |
||
|} |
|} |
||
</div> |
</div> |
||
| Line 812: | Line 785: | ||
* Strong performance from insurance businesses |
* Strong performance from insurance businesses |
||
* Stable holding cost, expected to remain at current level in 2026 |
* Stable holding cost, expected to remain at current level in 2026 |
||
* Net Income |
* Net Income |
||
* Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM |
* Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM |
||
| Line 818: | Line 790: | ||
==== Underlying earnings per share ==== |
==== Underlying earnings per share ==== |
||
In Euro |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t18" class="wikitable fintable" |
||
|+ Underlying earnings per share |
|+ Underlying earnings per share In Euro |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying earnings per share |
||
| style="text-align:right" | 3.59 |
|||
| style="text-align:right" | 3.86 |
| style="text-align:right" | 3.86 |
||
| style="text-align:right" | +8% |
| style="text-align:right" | +8% |
||
| Line 838: | Line 810: | ||
* -2% from forex |
* -2% from forex |
||
* including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback |
* including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback |
||
<!-- furniture --> |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 846: | Line 816: | ||
{{pdf page|22|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|22|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== |
=== Shareholders’ Equity === |
||
* In Euro billion |
* In Euro billion |
||
==== |
==== Shareholders’ equity{{fn ref|1|2=Shareholders’ equity Group share. Full Year 2025 Earnings}} ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t19" class="wikitable fintable" |
||
|+ |
|+ Shareholders’ equity (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 871: | Line 841: | ||
| style="text-align:right" | -6.8 |
| style="text-align:right" | -6.8 |
||
|- |
|- |
||
| style="text-align:left" | Shareholders' |
| style="text-align:left" | Total Shareholders' equity |
||
| style="text-align:right" | 49.9 |
| style="text-align:right" | 49.9 |
||
| style="text-align:right" | 45.5 |
| style="text-align:right" | 45.5 |
||
| Line 894: | Line 864: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t20" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | In Euro billion |
||
! class="col-s" style="text-align:right" | FY24 to FY25 |
! class="col-s" style="text-align:right" | FY24 to FY25 |
||
! class="col-s" style="text-align:right" | HY25 to FY25 |
! class="col-s" style="text-align:right" | HY25 to FY25 |
||
| Line 941: | Line 911: | ||
|} |
|} |
||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2= |
{{fn note|1=1|2=Shareholders’ equity Group share. Full Year 2025 Earnings}} |
||
</div> |
</div> |
||
| Line 950: | Line 919: | ||
* In Euro billion |
* In Euro billion |
||
==== Net Cash Remittance ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t21" class="wikitable fintable" |
||
|+ Net Cash Remittance |
|+ Net Cash Remittance |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col- |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | Remittance |
|||
| style="text-align:left" | Proceeds related to in-force treaties{{fn ref|2|2=€0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
|||
| style="text-align:right" | 0.6 |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Ordinary remittance |
|||
| style="text-align:right" | 7.1 |
| style="text-align:right" | 7.1 |
||
| style="text-align:right" | 7.5 |
| style="text-align:right" | 7.5 |
||
|- |
|||
| style="text-align:left" | Proceeds related to in-force treaties{{fn ref|2|2=2. €0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
|||
| style="text-align:right" | 0.6 |
|||
| style="text-align:right" | |
|||
|- |
|- |
||
| style="text-align:left" | Total |
| style="text-align:left" | Total |
||
| style="text-align:right" | 7.7 |
| style="text-align:right" | 7.7 |
||
| style="text-align:right" | |
| style="text-align:right" | 7.5 |
||
|- |
|- |
||
| style="text-align:left" | Remittance ratio{{fn ref|1|2=Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
| style="text-align:left" | Remittance ratio{{fn ref|1|2=1. Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
||
| style="text-align:right" | 82% |
| style="text-align:right" | 82% |
||
| style="text-align:right" | 82% |
| style="text-align:right" | 82% |
||
| Line 980: | Line 947: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t22" class="wikitable fintable" |
||
|+ Cash Position Bridge |
|||
|- |
|- |
||
| style="text-align:left" | FY24 Cash position |
|||
| style="text-align:right" | 4.0 |
|||
|- |
|- |
||
| style="text-align:left" | Net cash remittance from subsidiaries |
| style="text-align:left" | Net cash remittance from subsidiaries |
||
| Line 1,012: | Line 980: | ||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
{{fn note|1=1|2=1. Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
||
{{fn note|1=2|2=€0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
{{fn note|1=2|2=2. €0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
||
</div> |
</div> |
||
| Line 1,019: | Line 987: | ||
=== Solvency II at 224% === |
=== Solvency II at 224% === |
||
* In Euro billion |
|||
* In Euro billion Foreseeable dividends: €-4.8bn Provision for annual share buyback for 2026: €-1.25bn |
|||
* Foreseeable dividends: €-4.8bn |
|||
* Provision for annual share buyback for 2026: €-1.25bn |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t23" class="wikitable fintable" |
||
|+ In Euro billion |
|||
|+ Eligible Own Funds (EOF) / Solvency Capital Requirement (SCR) / Solvency II ratio bridge FY24–FY25 |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | Regulatory |
! class="col-s" style="text-align:right" | Regulatory & model changes |
||
! class="col-s" style="text-align:right" | Normalized capital generation |
! class="col-s" style="text-align:right" | Normalized capital generation |
||
! class="col-s" style="text-align:right" | Operating variance |
! class="col-s" style="text-align:right" | Operating variance |
||
! class="col-s" style="text-align:right" | Economic variance & FX |
! class="col-s" style="text-align:right" | Economic variance & FX |
||
! style="text-align: |
! class="col-s" style="text-align:right" | Dividend & annual share buyback |
||
! class="col-s" style="text-align:right" | Management actions, debt & other |
! class="col-s" style="text-align:right" | Management actions, debt & other |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 1,041: | Line 1,011: | ||
| style="text-align:right" | -0.4 |
| style="text-align:right" | -0.4 |
||
| style="text-align:right" | -2.1 |
| style="text-align:right" | -2.1 |
||
| style="text-align: |
| style="text-align:right" | -6.0 |
||
| style="text-align:right" | |
| style="text-align:right" | -0.1 |
||
| style="text-align:right" | 56.4 |
| style="text-align:right" | 56.4 |
||
|- |
|- |
||
| Line 1,051: | Line 1,021: | ||
| style="text-align:right" | -1pt |
| style="text-align:right" | -1pt |
||
| style="text-align:right" | +4pts |
| style="text-align:right" | +4pts |
||
| style="text-align: |
| style="text-align:right" | -24pts |
||
| style="text-align:right" | +2pts |
| style="text-align:right" | +2pts |
||
| style="text-align:right" | 224% |
| style="text-align:right" | 224% |
||
| Line 1,061: | Line 1,031: | ||
| style="text-align:right" | 0.0 |
| style="text-align:right" | 0.0 |
||
| style="text-align:right" | -1.2 |
| style="text-align:right" | -1.2 |
||
| style="text-align: |
| style="text-align:right" | 0.0 |
||
| style="text-align:right" | -0.2 |
| style="text-align:right" | -0.2 |
||
| style="text-align:right" | 25.2 |
| style="text-align:right" | 25.2 |
||
| Line 1,068: | Line 1,038: | ||
==== Key sensitivities ==== |
==== Key sensitivities ==== |
||
* Ratio as of December 31, 2025: 224% |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t24" class="wikitable fintable" |
||
|+ Ratio as of December 31, 2025 |
|||
|+ Key sensitivities |
|||
|- |
|- |
||
| style="text-align:left" | |
|||
| style="text-align:right" | 224% |
|||
|- |
|- |
||
| style="text-align:left" | Interest rate +50bps |
| style="text-align:left" | Interest rate +50bps |
||
| Line 1,117: | Line 1,085: | ||
{{pdf page|25|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|25|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Solvency II – impact of the end of grandfathering period and Solvency II revision === |
=== Solvency II – impact of the end of grandfathering period and Solvency II revision === |
||
* Ratio as of 31/12/2025: 224% |
|||
* Impact of the end of grandfathering period on January 1, 2026: -10pts to 215% |
|||
* Ratio as of 31/12/2025: 224% |
|||
* |
* Euro 2.4 billion grandfathered debt no longer eligible as capital from January 1, 2026 |
||
* Impact of Solvency II revision to come into effect in 1Q27: +17pts{{fn ref|1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
|||
* Euro 2.4 billion grandfathered debt no longer eligible as capital from January 1, 2026 |
|||
* No change expected in organic capital generation |
|||
* Impact of Solvency II revision to come into effect in 1Q27: +17pts{{fn ref|1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
|||
* No change expected in organic capital generation |
|||
* Additional capital flexibility |
* Additional capital flexibility |
||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
{{fn note|1=1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
||
| Line 1,130: | Line 1,098: | ||
{{pdf page|26|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|26|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
== Conclusion == |
== Conclusion == |
||
* Thomas Buberl, Group CEO |
* Thomas Buberl, Group CEO |
||
{{pdf page|27|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|27|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Conclusion === |
=== Conclusion === |
||
* Record results, at the top end of the target range while enhancing reserve prudence |
* Record results, at the top end of the target range while enhancing reserve prudence |
||
* All businesses in excellent shape, delivering strong growth and profitability |
* All businesses in excellent shape, delivering strong growth and profitability |
||
| Line 1,142: | Line 1,110: | ||
{{pdf page|28|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|28|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Q&A === |
=== Q&A === |
||
* Full Year 2025 Earnings |
|||
February 26, 2026 |
|||
{{pdf page|29|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|29|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== AXA Investor Relations – Keep in touch === |
=== AXA Investor Relations – Keep in touch === |
||
==== Meet our management ==== |
==== Meet our management ==== |
||
* March Roadshows Europe and US |
|||
* May 5 1Q25 Activity Indicators Paris |
|||
* March | Roadshows | Europe and US |
|||
* |
* June 2 BNP Paribas Exane CEO Conference Paris |
||
* June 2 |
* June 2-4 Goldman Sachs European Financials Conference Zurich |
||
* July 31 HY26 Earnings Release Paris |
|||
* June 2-4 | Goldman Sachs European Financials Conference | Zurich |
|||
* September 21 AXA Investor Day London |
|||
* July 31 | HY26 Earnings Release | Paris |
|||
* September 21 | AXA Investor Day | London |
|||
==== Contact us ==== |
==== Contact us ==== |
||
* Investor Relations +33 1 40 75 48 42 investor.relations@axa.com |
|||
* Investor Relations: +33 1 40 75 48 42 | investor.relations@axa.com |
|||
==== Follow us ==== |
==== Follow us ==== |
||
* www.axa.com |
* www.axa.com |
||
| Line 1,176: | Line 1,138: | ||
=== Gross financial debt and maturity breakdown as of December 31st, 2025 === |
=== Gross financial debt and maturity breakdown as of December 31st, 2025 === |
||
==== Gross financial debt{{fn ref|1,2}} ==== |
|||
* In Euro billion |
|||
==== Gross financial debt{{fn ref|1,2|2=1. Nominal debt. 2. In January 2026, AXA has called (i) the remaining T2 GF £139m due 2054 callable 2034 5.625% issued January 2014 and (ii) the T1 GF €250m perpetual callable 2010 floating issued January 2005.}} Contractual maturity breakdown ==== |
|||
* Debt gearing 20.6% 22.3% |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t25" class="wikitable fintable" |
||
|+ Gross financial debt ( |
|+ Gross financial debt (in Euro billion) and Debt gearing |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col- |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col- |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col- |
! class="col-s" style="text-align:right" | Jan 1st 2026 <br/> End of the grandfathering period |
||
|- |
|||
| style="text-align:left" | Debt gearing |
|||
| style="text-align:right" | 20.6% |
|||
| style="text-align:right" | 22.3% |
|||
| style="text-align:right" | - |
|||
|- |
|- |
||
| style="text-align:left" | Tier 1 |
| style="text-align:left" | Tier 1 |
||
| Line 1,204: | Line 1,167: | ||
| style="text-align:right" | 3.5 |
| style="text-align:right" | 3.5 |
||
| style="text-align:right" | 3.5 |
| style="text-align:right" | 3.5 |
||
| style="text-align:right" | 5.8 |
| style="text-align:right" | 5.8 {{fn ref|*|2=o/w €0.4bn redeemed in Jan 2026}} |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Total |
||
| style="text-align:right" | |
| style="text-align:right" | 19.2 |
||
| style="text-align:right" | |
| style="text-align:right" | 20.3 |
||
| style="text-align:right" | |
| style="text-align:right" | 20.3 |
||
|} |
|} |
||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
* Jan 1st 2026: End of the grandfathering period |
|||
{{fn note|1=*|2=o/w €0.4bn redeemed in Jan 2026}} |
|||
</div> |
|||
==== Contractual maturity breakdown ==== |
|||
* o/w €0.4bn redeemed in Jan 2026 |
|||
* Legend: Tier 1, Tier 2, Senior debt |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t26" class="wikitable fintable" |
||
|+ Contractual maturity breakdown ( |
|+ Contractual maturity breakdown (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Segment |
||
! class="col-s" style="text-align:right" | 2025 |
! class="col-s" style="text-align:right" | 2025 |
||
! class="col-s" style="text-align:right" | 2026 |
! class="col-s" style="text-align:right" | 2026 |
||
| Line 1,235: | Line 1,198: | ||
|- |
|- |
||
| style="text-align:left" | Senior debt |
| style="text-align:left" | Senior debt |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | 0.5 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | 0.9 |
| style="text-align:right" | 0.9 |
||
| style="text-align:right" | 1.5 |
| style="text-align:right" | 1.5 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
|- |
|- |
||
| style="text-align:left" | Tier 2 |
| style="text-align:left" | Tier 2 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | 0.7 |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | - |
|||
| style="text-align:right" | 10.8 |
| style="text-align:right" | 10.8 |
||
| style="text-align:right" | 0.7 |
|||
|- |
|||
| style="text-align:left" | Tier 1 |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | 4.6 |
| style="text-align:right" | 4.6 |
||
| style="text-align:right" | |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | o/w Grandfathered debt |
||
| style="text-align:right" | |
|||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| Line 1,264: | Line 1,239: | ||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 0.7 |
|||
| style="text-align:right" | |
| style="text-align:right" | |
||
|} |
|||
</div> |
|||
==== o/w Grandfathered debt (Contractual maturity breakdown) ==== |
|||
<div style="overflow-x:auto"> |
|||
{| id="t28" class="wikitable fintable" |
|||
|- |
|||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | 2025 |
|||
! class="col-s" style="text-align:right" | 2026 |
|||
! class="col-s" style="text-align:right" | 2027 |
|||
! class="col-s" style="text-align:right" | 2028 |
|||
! class="col-s" style="text-align:right" | 2029 |
|||
! class="col-s" style="text-align:right" | 2030 |
|||
! class="col-s" style="text-align:right" | 2031-2039 |
|||
! class="col-s" style="text-align:right" | ≥2040 |
|||
! class="col-s" style="text-align:right" | Undated |
|||
|- |
|- |
||
| style="text-align:left" | Tier 1 |
| style="text-align:left" | Tier 1 |
||
| Line 1,309: | Line 1,265: | ||
</div> |
</div> |
||
==== Economic maturity breakdown{{fn ref|3|2= |
==== Economic maturity breakdown{{fn ref|3|2=Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.}} ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t27" class="wikitable fintable" |
||
|+ Economic maturity breakdown ( |
|+ Economic maturity breakdown (in Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Segment |
||
! class="col-s" style="text-align:right" | 2025 |
! class="col-s" style="text-align:right" | 2025 |
||
! class="col-s" style="text-align:right" | 2026 |
! class="col-s" style="text-align:right" | 2026 |
||
| Line 1,327: | Line 1,283: | ||
|- |
|- |
||
| style="text-align:left" | Senior debt |
| style="text-align:left" | Senior debt |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | 0.1 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | 1.5 |
|||
| style="text-align:right" | 0.5 |
| style="text-align:right" | 0.5 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | 0.9 |
|||
| style="text-align:right" | 1.5 |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
|- |
|- |
||
| style="text-align:left" | Tier 2 |
| style="text-align:left" | Tier 2 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | 2.4 |
| style="text-align:right" | 2.4 |
||
| style="text-align:right" | 0. |
| style="text-align:right" | 0.1 |
||
| style="text-align:right" | 2.0 |
| style="text-align:right" | 2.0 |
||
| style="text-align:right" | 0. |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | 6.4 |
| style="text-align:right" | 6.4 |
||
| style="text-align:right" | - |
|||
| style="text-align:right" | 0.7 |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | |
|||
|- |
|- |
||
| style="text-align:left" | Tier 1 |
| style="text-align:left" | Tier 1 |
||
| style="text-align:right" | |
| style="text-align:right" | - |
||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | - |
|||
| style="text-align:right" | 0.4 |
|||
| style="text-align:right" | 0.5 |
|||
| style="text-align:right" | 4.0 |
|||
|- |
|||
| style="text-align:left" | o/w Grandfathered debt |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | 0.9 |
|||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 4.0 |
|||
| style="text-align:right" | |
| style="text-align:right" | |
||
|} |
|||
</div> |
|||
==== o/w Grandfathered debt (Economic maturity breakdown) ==== |
|||
<div style="overflow-x:auto"> |
|||
{| id="t30" class="wikitable fintable" |
|||
|- |
|||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | 2025 |
|||
! class="col-s" style="text-align:right" | 2026 |
|||
! class="col-s" style="text-align:right" | 2027 |
|||
! class="col-s" style="text-align:right" | 2028 |
|||
! class="col-s" style="text-align:right" | 2029 |
|||
! class="col-s" style="text-align:right" | 2030 |
|||
! class="col-s" style="text-align:right" | 2031-2039 |
|||
! class="col-s" style="text-align:right" | ≥2040 |
|||
! class="col-s" style="text-align:right" | Undated |
|||
|- |
|- |
||
| style="text-align:left" | Tier 1 |
| style="text-align:left" | Tier 1 |
||
| Line 1,402: | Line 1,351: | ||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Nominal debt.}} |
|||
{{fn note|1=1,2|2=1. Nominal debt. 2. In January 2026, AXA has called (i) the remaining T2 GF £139m due 2054 callable 2034 5.625% issued January 2014 and (ii) the T1 GF €250m perpetual callable 2010 floating issued January 2005.}} |
|||
{{fn note|1=2|2=In January 2026, AXA has called (i) the remaining T2 GF £139m due 2054 callable 2034 5.625% issued January 2014 and (ii) the T1 GF €250m perpetual callable 2010 floating issued January 2005.}} |
|||
{{fn note|1=3|2=3. Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.}} |
|||
{{fn note|1=3|2=Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.}} |
|||
</div> |
</div> |
||
| Line 1,409: | Line 1,359: | ||
=== General Account Invested Assets === |
=== General Account Invested Assets === |
||
==== FY25 Total General Account invested assets ==== |
|||
* Duration gap at -0.4 year |
* Duration gap at -0.4 year |
||
* Euro 450 billion |
|||
* Fixed income |
|||
<div style="overflow-x:auto"> |
|||
* Real estate |
|||
{| id="t31" class="wikitable fintable" |
|||
* Infrastructure equity |
|||
|+ FY25 Total General Account invested assets: Euro 450 billion |
|||
* Listed equities |
|||
|- |
|||
* Private equity and hedge funds |
|||
| style="text-align:left" | Fixed income |
|||
* Cash |
|||
| style="text-align:right" | 77% |
|||
* Policy loans |
|||
|- |
|||
| style="text-align:left" | Real estate |
|||
| style="text-align:right" | 9% |
|||
|- |
|||
| style="text-align:left" | Infrastructure equity |
|||
| style="text-align:right" | 2% |
|||
|- |
|||
| style="text-align:left" | Listed equities |
|||
| style="text-align:right" | 2% |
|||
|- |
|||
| style="text-align:left" | Private equity and hedge funds |
|||
| style="text-align:right" | 5% |
|||
|- |
|||
| style="text-align:left" | Cash |
|||
| style="text-align:right" | 4% |
|||
|- |
|||
| style="text-align:left" | Policy loans |
|||
| style="text-align:right" | 0% |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t28" class="wikitable fintable" |
||
|+ Invested assets (100%) In Euro billion |
|+ Invested assets (100%) In Euro billion |
||
|- |
|- |
||
| Line 1,459: | Line 1,391: | ||
| style="text-align:right" | 27% |
| style="text-align:right" | 27% |
||
|- |
|- |
||
| style="text-align:left" | o/w Other fixed income |
| style="text-align:left" | o/w Other fixed income{{fn ref|1|2=Other fixed income includes Asset Backed Securities (Euro 25 billion), Residential Loans (Euro 16 billion), Commercial & Agricultural Loans (Euro 7 billion) and Agency Pools (Euro 8 billion).}} |
||
| style="text-align:right" | 56 |
| style="text-align:right" | 56 |
||
| style="text-align:right" | 13% |
| style="text-align:right" | 13% |
||
| Line 1,471: | Line 1,403: | ||
| style="text-align:right" | 2% |
| style="text-align:right" | 2% |
||
|- |
|- |
||
| style="text-align:left" | Listed equities |
| style="text-align:left" | Listed equities{{fn ref|2|2=Includes hedges. Listed equities excluding hedges at Euro 14 billion.}} |
||
| style="text-align:right" | 10 |
| style="text-align:right" | 10 |
||
| style="text-align:right" | 2% |
| style="text-align:right" | 2% |
||
|- |
|- |
||
| style="text-align:left" | Private equity and hedge funds |
| style="text-align:left" | Private equity and hedge funds{{fn ref|3|2=Includes Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).}} |
||
| style="text-align:right" | 23 |
| style="text-align:right" | 23 |
||
| style="text-align:right" | 5% |
| style="text-align:right" | 5% |
||
| Line 1,487: | Line 1,419: | ||
| style="text-align:right" | 0% |
| style="text-align:right" | 0% |
||
|- |
|- |
||
| style="text-align:left" | Total Insurance Invested Assets |
| style="text-align:left" | Total Insurance Invested Assets{{fn ref|4|2=Please refer to the financial supplement for more details.}} |
||
| style="text-align:right" | 450 |
| style="text-align:right" | 450 |
||
| style="text-align:right" | 100% |
| style="text-align:right" | 100% |
||
| Line 1,494: | Line 1,426: | ||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Other fixed income includes Asset Backed Securities (Euro 25 billion), Residential Loans (Euro 16 billion), Commercial & Agricultural Loans (Euro 7 billion) and Agency Pools (Euro 8 billion).}} |
{{fn note|1=1|2=Other fixed income includes Asset Backed Securities (Euro 25 billion), Residential Loans (Euro 16 billion), Commercial & Agricultural Loans (Euro 7 billion) and Agency Pools (Euro 8 billion).}} |
||
{{fn note|1=2|2=Includes hedges. Listed equities excluding hedges at Euro 14 billion.}} |
{{fn note|1=2|2=Includes hedges. Listed equities excluding hedges at Euro 14 billion.}} |
||
{{fn note|1=3|2=Includes Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).}} |
{{fn note|1=3|2=Includes Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).}} |
||
| Line 1,504: | Line 1,436: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t29" class="wikitable fintable" |
||
|+ Invested assets (100%) In Euro billion |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col- |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col- |
! class="col-s" style="text-align:right" | % of total G/A{{fn ref|1|2=G/A: General Account}} portfolio |
||
! style="text-align:left" | Comments |
! style="text-align:left" | Comments |
||
|- |
|- |
||
| Line 1,541: | Line 1,474: | ||
| style="text-align:left" | |
| style="text-align:left" | |
||
|- |
|- |
||
| style="text-align:left" | < |
| style="text-align:left" | <b>Total Structured and Private Credit Assets</b> |
||
| style="text-align:right" | < |
| style="text-align:right" | <b>69</b> |
||
| style="text-align:right" | < |
| style="text-align:right" | <b>15%</b> |
||
| style="text-align:left" | o/w 54% participating |
| style="text-align:left" | o/w 54% participating |
||
|} |
|} |
||
| Line 1,557: | Line 1,490: | ||
==== FY25 Fixed Income Reinvestment ==== |
==== FY25 Fixed Income Reinvestment ==== |
||
<div style="overflow-x:auto"> |
|||
* Euro 57 billion |
|||
{| id="t30" class="wikitable fintable" |
|||
|+ FY25 Fixed Income Reinvestment (Total: Euro 57 billion) |
|||
* Government bonds & related (32%) – Average rating: AA |
|||
|- |
|||
| style="text-align:left" | Government bonds & related (32%) – Average rating: AA |
|||
| style="text-align:right" | 32% |
|||
|- |
|||
* ABS/CLO/IG fund financing (21%) |
|||
| style="text-align:left" | Investment grade credit (40%)- Average rating: A |
|||
| style="text-align:right" | 40% |
|||
* Below investment grade credit (7%) |
|||
|- |
|||
| style="text-align:left" | ABS/CLO/IG fund financing (21%) |
|||
| style="text-align:right" | 21% |
|||
|- |
|||
| style="text-align:left" | Below investment grade credit (7%) |
|||
| style="text-align:right" | 7% |
|||
|} |
|||
</div> |
|||
==== FY25 Fixed Income Reinvestment Yield ==== |
==== FY25 Fixed Income Reinvestment Yield ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t31" class="wikitable fintable" |
||
|- |
|||
! style="text-align:left" | Category |
|||
! class="col-s" style="text-align:right" | Yield |
|||
|- |
|||
| style="text-align:left" | Public fixed income{{fn ref|1|2=Government and Corporate bonds and related.}} |
|||
| style="text-align:right" | 3.5% |
|||
|- |
|- |
||
| style="text-align:left" | Private & Structured fixed income{{fn ref|2|2=Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).}} |
|||
| style="text-align:right" | 4.7% |
|||
! style="text-align:left" | Private & Structured fixed income{{fn ref|2|2=Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).}} |
|||
! class="col-s" style="text-align:right" | Total fixed income |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Total fixed income |
||
| style="text-align:left" | 4.7% |
|||
| style="text-align:right" | 3.9% |
| style="text-align:right" | 3.9% |
||
|} |
|} |
||
| Line 1,583: | Line 1,528: | ||
* Euro 57 billion fixed income invested at 3.9% |
* Euro 57 billion fixed income invested at 3.9% |
||
* Average duration of 9 years |
* Average duration of 9 years |
||
* Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY) |
* Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY) |
||
| Line 1,592: | Line 1,536: | ||
{{fn note|1=2|2=Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).}} |
{{fn note|1=2|2=Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).}} |
||
</div> |
</div> |
||
* Full Year 2025 Earnings |
|||
{{pdf page|36|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|36|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,601: | Line 1,547: | ||
{{pdf page|37|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|37|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== AXA XL Insurance – Large Commercial & Specialty business === |
=== AXA XL Insurance – Large Commercial & Specialty business === |
||
==== Well diversified across lines of business and geographies ==== |
==== Well diversified across lines of business and geographies ==== |
||
<div style="overflow-x:auto"> |
|||
{| id="t32" class="wikitable fintable" |
|||
|+ $19bn FY25 GWP by line of business |
|||
|- |
|||
| style="text-align:left" | Casualty |
|||
| style="text-align:right" | 35% |
|||
|- |
|||
| style="text-align:left" | Property |
|||
| style="text-align:right" | 29% |
|||
|- |
|||
| style="text-align:left" | Specialty |
|||
| style="text-align:right" | 19% |
|||
|- |
|||
| style="text-align:left" | Professional lines{{fn ref|1|2=Including Cyber;}} |
|||
| style="text-align:right" | 17% |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
* $19bn FY25 GWP by line of business |
|||
{| id="t33" class="wikitable fintable" |
|||
* Casualty (35%) |
|||
|+ $19bn FY25 GWP by geography |
|||
* Property (29%) |
|||
|- |
|||
* Specialty (19%) |
|||
| style="text-align:left" | Americas |
|||
* Professional lines{{fn ref|1|2=Including Cyber}} (17%) |
|||
| style="text-align:right" | 46% |
|||
|- |
|||
* $19bn FY25 GWP by geography |
|||
| style="text-align:left" | Europe & APAC |
|||
* Americas (46%) |
|||
| style="text-align:right" | 35% |
|||
* Europe & APAC (35%) |
|||
|- |
|||
* UK & Lloyds (19%) |
|||
| style="text-align:left" | UK & Lloyds |
|||
| style="text-align:right" | 19% |
|||
|} |
|||
</div> |
|||
==== Leading market positions across lines ==== |
==== Leading market positions across lines ==== |
||
* Top 3 globally |
* Top 3 globally |
||
* Multinational Programs{{fn ref|2|2=Source: McKinsey;}} |
|||
* |
* Marine{{fn ref|3|2=Source: Aon, Guy Carpenter, and Global Market Insights;}} |
||
* Fine Art & Specie{{fn ref|4|2=Source: Industry Research Biz (January 2026).}} |
|||
* Marine{{fn ref|3|2=Source: Aon, Guy Carpenter, and Global Market Insights}} |
|||
* Fine Art & Specie{{fn ref|4|2=Source: Industry Research Biz (January 2026)}} |
|||
==== Managing the cycle to deliver consistent profitability ==== |
==== Managing the cycle to deliver consistent profitability ==== |
||
* Profitability vs Ex-price growth (%): |
|||
* Property |
|||
* Bubble chart with axes: Ex-price growth (%) (x-axis) and Profitability (y-axis); segments shown: Property (high profitability, high ex-price growth), Specialty, Casualty, Professional lines (lower profitability, lower ex-price growth) |
|||
* Specialty |
|||
* Casualty |
|||
* Professional lines |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Including Cyber}} |
{{fn note|1=1|2=Including Cyber;}} |
||
{{fn note|1=2|2=Source: McKinsey}} |
{{fn note|1=2|2=Source: McKinsey;}} |
||
{{fn note|1=3|2=Source: Aon, Guy Carpenter, and Global Market Insights}} |
{{fn note|1=3|2=Source: Aon, Guy Carpenter, and Global Market Insights;}} |
||
{{fn note|1=4|2=Source: Industry Research Biz (January 2026)}} |
{{fn note|1=4|2=Source: Industry Research Biz (January 2026).}} |
||
</div> |
</div> |
||
{{pdf page|38|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|38|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – Focus on Reserves === |
=== P&C – Focus on Reserves === |
||
==== Claims reserves ratio ==== |
|||
(Net undiscounted claims reserves/Net earned premiums) |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t34" class="wikitable fintable" |
||
|+ Claims reserves ratio |
|+ Claims reserves ratio (Net undiscounted claims reserves/Net earned premiums) |
||
|- |
|- |
||
! style="text-align: |
! colspan="5" style="text-align:center" | IFRS4 |
||
! |
! colspan="4" style="text-align:center" | IFRS17 |
||
|- |
|||
! style="text-align:left" | FY18 |
|||
! class="col-s" style="text-align:right" | FY19 |
! class="col-s" style="text-align:right" | FY19 |
||
! class="col-s" style="text-align:right" | FY20 |
! class="col-s" style="text-align:right" | FY20 |
||
! class="col-s" style="text-align:right" | FY21 |
! class="col-s" style="text-align:right" | FY21 |
||
! class="col-s" style="text-align:right" | FY22 |
! class="col-s" style="text-align:right" | FY22 |
||
! class="col-s" style="text-align:right" | FY22 |
! class="col-s" style="text-align:right" | FY22 |
||
! class="col-s" style="text-align:right" | FY23 |
! class="col-s" style="text-align:right" | FY23 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 179% |
||
| style="text-align:right" | 179% |
|||
| style="text-align:right" | 185% |
| style="text-align:right" | 185% |
||
| style="text-align:right" | 193% |
| style="text-align:right" | 193% |
||
| Line 1,669: | Line 1,631: | ||
|} |
|} |
||
</div> |
</div> |
||
==== Technical reserves ratio ==== |
|||
(Net undiscounted technical reserves{{fn ref|1|2=Includes net undiscounted claims reserves and unearned premium reserves.}}/Net earned premiums) |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t35" class="wikitable fintable" |
||
|+ Technical reserves ratio (Net undiscounted technical reserves{{fn ref|1|2=Includes net undiscounted claims reserves and unearned premium reserves.}}/Net earned premiums) |
|||
|+ Technical reserves ratio |
|||
|- |
|- |
||
! style="text-align: |
! colspan="5" style="text-align:center" | IFRS4 |
||
! |
! colspan="4" style="text-align:center" | IFRS17 |
||
|- |
|||
! style="text-align:left" | FY18 |
|||
! class="col-s" style="text-align:right" | FY19 |
! class="col-s" style="text-align:right" | FY19 |
||
! class="col-s" style="text-align:right" | FY20 |
! class="col-s" style="text-align:right" | FY20 |
||
! class="col-s" style="text-align:right" | FY21 |
! class="col-s" style="text-align:right" | FY21 |
||
! class="col-s" style="text-align:right" | FY22 |
! class="col-s" style="text-align:right" | FY22 |
||
! class="col-s" style="text-align:right" | FY22 |
! class="col-s" style="text-align:right" | FY22 |
||
! class="col-s" style="text-align:right" | FY23 |
! class="col-s" style="text-align:right" | FY23 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 213% |
||
| style="text-align:right" | 213% |
|||
| style="text-align:right" | 227% |
| style="text-align:right" | 227% |
||
| style="text-align:right" | 233% |
| style="text-align:right" | 233% |
||
| Line 1,708: | Line 1,668: | ||
=== P&C – 2026 Simplified Group Nat Cat Reinsurance Program{{fn ref|1|2=Excludes local reinsurance covers;}} === |
=== P&C – 2026 Simplified Group Nat Cat Reinsurance Program{{fn ref|1|2=Excludes local reinsurance covers;}} === |
||
In Euro |
|||
==== Insurance segment (occurrence protection) ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t36" class="wikitable fintable" |
||
|+ Insurance segment (occurrence protection |
|+ Insurance segment (occurrence protection) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Peril |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Capacity |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Retention |
||
! class="col-s" style="text-align:right" | Europe Earthquake |
|||
! class="col-s" style="text-align:right" | NA Hurricane |
|||
! class="col-s" style="text-align:right" | NA Earthquake |
|||
! class="col-s" style="text-align:right" | Per other perils{{fn ref|3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
|||
! style="text-align:left" | Reinsurance segment (illustrative) — Alternative Capital & Cat Bonds |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | EU Windstorm |
||
| style="text-align:right" | 4.0bn |
| style="text-align:right" | 4.0bn |
||
| style="text-align:right" | 600m |
|||
|- |
|||
| style="text-align:left" | Europe Flood |
|||
| style="text-align:right" | 2.1bn |
| style="text-align:right" | 2.1bn |
||
| style="text-align:right" | 450m |
|||
|- |
|||
| style="text-align:left" | Europe Earthquake |
|||
| style="text-align:right" | 2.1bn |
| style="text-align:right" | 2.1bn |
||
| style="text-align:right" | 400m |
|||
|- |
|||
| style="text-align:left" | NA Hurricane |
|||
| style="text-align:right" | 1.2bn |
| style="text-align:right" | 1.2bn |
||
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
|||
|- |
|||
| style="text-align:left" | NA Earthquake |
|||
| style="text-align:right" | 1.2bn |
| style="text-align:right" | 1.2bn |
||
| style="text-align:right" | |
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
||
| style="text-align:left" | |
|||
|- |
|- |
||
| style="text-align:left" | Per other perils{{fn ref|3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
|||
| style="text-align:left" | Retention |
|||
| style="text-align:right" | |
| style="text-align:right" | 1.2bn |
||
| style="text-align:right" | 450m |
|||
| style="text-align:right" | 400m |
| style="text-align:right" | 400m |
||
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
|||
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
|||
| style="text-align:right" | 400m |
|||
| style="text-align:left" | |
|||
|} |
|} |
||
</div> |
</div> |
||
==== Reinsurance segment (illustrative) ==== |
|||
* Alternative Capital & Cat Bonds |
|||
* Stable retention levels maintained in 2026 as in 2025 |
* Stable retention levels maintained in 2026 as in 2025 |
||
| Line 1,752: | Line 1,719: | ||
{{pdf page|40|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|40|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – AXA Group earnings deviation with different levels of Nat Cat cost{{fn ref|1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). |
=== P&C – AXA Group earnings deviation with different levels of Nat Cat cost{{fn ref|1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance).}} in 2026 === |
||
In Euro billion (net of reinsurance) |
|||
==== Group underlying earnings deviation to average Nat Cat charges in 2026 ==== |
==== Group underlying earnings deviation to average Nat Cat charges in 2026 net of reinsurance, post-tax ==== |
||
net of reinsurance, post-tax net of reinsurance, pre-tax |
|||
* More severe years: Negative deviation in ca. 40% of cases |
|||
* Less severe years: Positive deviation in ca. 60% of cases |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t37" class="wikitable" |
||
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 |
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Return Period |
||
! style="text-align:right" | Percentile |
! style="text-align:right" | Percentile |
||
! style="text-align:right" | Deviation |
! style="text-align:right" | Deviation |
||
|- |
|- |
||
| style="text-align:left" | 1/20y |
| style="text-align:left" | 1/20y |
||
| style="text-align:right" | |
| style="text-align:right" | (5th) |
||
| style="text-align:right" | €-1.2bn |
| style="text-align:right" | €-1.2bn |
||
|- |
|- |
||
| style="text-align:left" | 1/10y |
| style="text-align:left" | 1/10y |
||
| style="text-align:right" | |
| style="text-align:right" | (10th) |
||
| style="text-align:right" | €-0.8bn |
| style="text-align:right" | €-0.8bn |
||
|- |
|- |
||
| style="text-align:left" | 1/5y |
| style="text-align:left" | 1/5y |
||
| style="text-align:right" | |
| style="text-align:right" | (20th) |
||
| style="text-align:right" | €-0.4bn |
| style="text-align:right" | €-0.4bn |
||
|- |
|- |
||
| style="text-align:left" | Median |
| style="text-align:left" | Median |
||
| style="text-align:right" | 50th |
| style="text-align:right" | (50th) |
||
| style="text-align:right" | €+0.1bn |
| style="text-align:right" | €+0.1bn |
||
|- |
|- |
||
| style="text-align:left" | 1/5y |
| style="text-align:left" | 1/5y |
||
| style="text-align:right" | |
| style="text-align:right" | (80th) |
||
| style="text-align:right" | €+0.5bn |
| style="text-align:right" | €+0.5bn |
||
|- |
|- |
||
| style="text-align:left" | 1/10y |
| style="text-align:left" | 1/10y |
||
| style="text-align:right" | |
| style="text-align:right" | (90th) |
||
| style="text-align:right" | €+0.7bn |
| style="text-align:right" | €+0.7bn |
||
|- |
|- |
||
| style="text-align:left" | 1/20y |
| style="text-align:left" | 1/20y |
||
| style="text-align:right" | |
| style="text-align:right" | (95th) |
||
| style="text-align:right" | €+0.8bn |
| style="text-align:right" | €+0.8bn |
||
|} |
|} |
||
</div> |
</div> |
||
==== Average Expected Nat Cat charges net of reinsurance, pre-tax ==== |
|||
* More severe years — Negative deviation in ca. 40% of cases |
|||
* Less severe years — Positive deviation in ca. 60% of cases |
|||
==== Average Expected Nat Cat charges ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t38" class="wikitable" |
||
|+ Average Expected Nat Cat charges |
|+ Average Expected Nat Cat charges |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Year |
||
! style="text-align:right" | |
! style="text-align:right" | Charges (€bn) |
||
! style="text-align:right" | |
! style="text-align:right" | Estimated impact on GEP |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 2025 |
||
| style="text-align:right" | 2.6 |
| style="text-align:right" | 2.6 |
||
| style="text-align:right" | ca. 4.5% |
|||
|- |
|||
| style="text-align:left" | 2026 |
|||
| style="text-align:right" | 2.7 |
| style="text-align:right" | 2.7 |
||
|- |
|||
| style="text-align:left" | Estimated impact on GEP |
|||
| style="text-align:right" | ca. 4.5% |
|||
| style="text-align:right" | ca. 4.5% |
| style="text-align:right" | ca. 4.5% |
||
|} |
|} |
||
| Line 1,823: | Line 1,789: | ||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). |
{{fn note|1=1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance).}} |
||
</div> |
</div> |
||
{{pdf page|41|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|41|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Contents === |
=== Contents === |
||
* 1. Debt and Invested Assets p.31 |
* 1. Debt and Invested Assets p.31 |
||
* 2. Additional P&C disclosures p.36 |
* 2. Additional P&C disclosures p.36 |
||
* 3. Additional IFRS17 disclosures p.41 |
* 3. Additional IFRS17 disclosures p.41 |
||
* 4. Sustainability p.44 |
|||
{{pdf page|42|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|42|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – Margin Analysis === |
=== P&C – Margin Analysis === |
||
==== Technical Result ==== |
|||
In Euro million (pre-tax) |
*In Euro million (pre-tax)* |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t39" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,845: | Line 1,816: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Current Accident Year Undiscounted Technical Margin |
||
| style="text-align:right" | 2,778 |
| style="text-align:right" | 2,778 |
||
| style="text-align:right" | +707 |
| style="text-align:right" | +707 |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t41" class="wikitable fintable" |
|||
|- |
|- |
||
| style="text-align:left" | Gross Earned Premiums |
| style="text-align:left" | Gross Earned Premiums |
||
| Line 1,869: | Line 1,835: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t40" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,875: | Line 1,841: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Current Accident Year Discounting |
||
| style="text-align:right" | 2,009 |
| style="text-align:right" | 2,009 |
||
| style="text-align:right" | +115 |
| style="text-align:right" | +115 |
||
| Line 1,898: | Line 1,864: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t41" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,904: | Line 1,870: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Prior Years' Reserve Development (PYD) |
||
| style="text-align:right" | 622 |
| style="text-align:right" | 622 |
||
| style="text-align:right" | -341 |
| style="text-align:right" | -341 |
||
| Line 1,914: | Line 1,880: | ||
</div> |
</div> |
||
* FY25 sensitivity to Current Accident Year discount rate changes{{fn ref|2}} |
|||
<div style="overflow-x:auto"> |
|||
* +25bps: €+0.2bn |
|||
{| id="t44" class="wikitable" |
|||
* -25bps: €-0.2bn |
|||
|+ FY25 sensitivity to Current Accident Year discount rate changes{{fn ref|2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}} |
|||
|- |
|||
! style="text-align:left" | +25bps |
|||
! style="text-align:right" | -25bps |
|||
|- |
|||
| style="text-align:left" | €+0.2bn |
|||
| style="text-align:right" | €-0.2bn |
|||
|} |
|||
</div> |
|||
==== Financial Result ==== |
|||
In Euro million (pre-tax) |
*In Euro million (pre-tax)* |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t42" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,936: | Line 1,894: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Investment Income |
||
| style="text-align:right" | 3,988 |
| style="text-align:right" | 3,988 |
||
| style="text-align:right" | +435 |
| style="text-align:right" | +435 |
||
| Line 1,948: | Line 1,906: | ||
| style="text-align:right" | |
| style="text-align:right" | |
||
|- |
|- |
||
| style="text-align:left" | FY25 Reinvestment yield{{fn ref|1 |
| style="text-align:left" | FY25 Reinvestment yield{{fn ref|1}} |
||
| style="text-align:right" | 4.3% |
| style="text-align:right" | 4.3% |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| Line 1,955: | Line 1,913: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t43" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,961: | Line 1,919: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Insurance Finance Expenses |
||
| style="text-align:right" | -1,358 |
| style="text-align:right" | -1,358 |
||
| style="text-align:right" | -235 |
| style="text-align:right" | -235 |
||
| Line 1,975: | Line 1,933: | ||
</div> |
</div> |
||
* 2026e Insurance Finance Expenses (pre-tax): ~ €-1.4bn |
|||
<div style="overflow-x:auto"> |
|||
* Sensitivity of 2026e Insurance Finance Expenses to changes in 2025 current AY Discount |
|||
{| id="t47" class="wikitable" |
|||
* +25bps: ~ €-50m |
|||
|+ 2026e Insurance Finance Expenses (pre-tax): ~ €-1.4bn — Sensitivity of 2026e Insurance Finance Expenses to changes in 2025 current AY Discount |
|||
* -25bps: ~€+50m |
|||
|- |
|||
! style="text-align:left" | +25bps |
|||
! style="text-align:right" | -25bps |
|||
|- |
|||
| style="text-align:left" | ~ €-50m |
|||
| style="text-align:right" | ~€+50m |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t44" class="wikitable fintable" |
||
|+ Full Year 2025 Earnings |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,995: | Line 1,945: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying Earnings before tax |
||
| style="text-align:right" | 8,040 |
| style="text-align:right" | 8,040 |
||
| style="text-align:right" | +681 |
| style="text-align:right" | +681 |
||
| Line 2,007: | Line 1,957: | ||
| style="text-align:right" | -10 |
| style="text-align:right" | -10 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying Earnings |
||
| style="text-align:right" | 5,872 |
| style="text-align:right" | 5,872 |
||
| style="text-align:right" | +501 |
| style="text-align:right" | +501 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Growth vs. FY24 (at constant FX) |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | +9% |
| style="text-align:right" | +9% |
||
| Line 2,017: | Line 1,967: | ||
</div> |
</div> |
||
Changes versus FY24 at constant FX. 1. Reinvestment yield on fixed income assets. 2. Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve. |
|||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
|||
{{fn note|1=2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}} |
|||
</div> |
|||
{{pdf page|43|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|43|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== L&H – Margin Analysis === |
=== L&H – Margin Analysis === |
||
* Includes scope impact |
* Includes scope impact |
||
==== Technical Result ==== |
==== Technical Result ==== |
||
In Euro million, pre-tax |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t45" class="wikitable fintable" |
||
|+ Technical Result |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 2,037: | Line 1,984: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Short-term Technical Margin |
||
| style="text-align:right" | 479 |
| style="text-align:right" | 479 |
||
| style="text-align:right" | +60 |
| style="text-align:right" | +60 |
||
| Line 2,048: | Line 1,995: | ||
| style="text-align:right" | 97.2% |
| style="text-align:right" | 97.2% |
||
| style="text-align:right" | -0.1pts |
| style="text-align:right" | -0.1pts |
||
|} |
|||
</div> |
|||
* Incl. recapture of Laya |
|||
<div style="overflow-x:auto"> |
|||
{| id="t50" class="wikitable fintable" |
|||
|- |
|- |
||
| style="text-align:left" | Incl. recapture of Laya |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Long-term Technical Margin |
||
| style="text-align:right" | 2,804 |
| style="text-align:right" | 2,804 |
||
| style="text-align:right" | +156 |
| style="text-align:right" | +156 |
||
| Line 2,071: | Line 2,011: | ||
| style="text-align:right" | -150 |
| style="text-align:right" | -150 |
||
| style="text-align:right" | -58 |
| style="text-align:right" | -58 |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t51" class="wikitable fintable" |
|||
|+ Life & Health FY25 CSM Key Sensitivities (in Euro billion) |
|||
|- |
|||
! style="text-align:left" | Baseline |
|||
! class="col-s" style="text-align:right" | 33.3 |
|||
|- |
|||
| style="text-align:left" | Interest rates +50bps |
|||
| style="text-align:right" | -0.8 |
|||
|- |
|||
| style="text-align:left" | Interest rates -50bps |
|||
| style="text-align:right" | 0.6 |
|||
|- |
|||
| style="text-align:left" | Sovereign spreads +50bps |
|||
| style="text-align:right" | -1.9 |
|||
|- |
|||
| style="text-align:left" | Sovereign spreads -50bps |
|||
| style="text-align:right" | 1.9 |
|||
|- |
|||
| style="text-align:left" | Corporate spread +50bps |
|||
| style="text-align:right" | -0.8 |
|||
|- |
|||
| style="text-align:left" | Corporate spread -50bps |
|||
| style="text-align:right" | 0.7 |
|||
|- |
|||
| style="text-align:left" | Equities +25% |
|||
| style="text-align:right" | 1.8 |
|||
|- |
|||
| style="text-align:left" | Equities -25% |
|||
| style="text-align:right" | -2.2 |
|||
|} |
|} |
||
</div> |
</div> |
||
==== Financial Result ==== |
==== Financial Result ==== |
||
In Euro million, pre-tax |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t46" class="wikitable fintable" |
||
|+ Financial Result |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 2,117: | Line 2,025: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Investment Income (non-VFA only) |
||
| style="text-align:right" | 2,484 |
| style="text-align:right" | 2,484 |
||
| style="text-align:right" | -1 |
| style="text-align:right" | -1 |
||
| Line 2,132: | Line 2,040: | ||
| style="text-align:right" | 3.8% |
| style="text-align:right" | 3.8% |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t53" class="wikitable fintable" |
|||
|- |
|||
! style="text-align:left" | |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
! class="col-s" style="text-align:right" | Change |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Insurance Finance Expenses (non-VFA only) |
||
| style="text-align:right" | -1,538 |
| style="text-align:right" | -1,538 |
||
| style="text-align:right" | -9 |
| style="text-align:right" | -9 |
||
| Line 2,155: | Line 2,054: | ||
|} |
|} |
||
</div> |
</div> |
||
==== Life & Health FY25 CSM Key Sensitivities ==== |
|||
(in Euro billion) |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t47" class="wikitable fintable" |
||
|- |
|||
| style="text-align:left" | <b>Baseline</b> |
|||
| style="text-align:right" | <b>33.3</b> |
|||
|- |
|||
| style="text-align:left" | Interest rates +50bps |
|||
| style="text-align:right" | -0.8 |
|||
|- |
|||
| style="text-align:left" | Interest rates -50bps |
|||
| style="text-align:right" | 0.6 |
|||
|- |
|||
| style="text-align:left" | Sovereign spreads +50bps |
|||
| style="text-align:right" | -1.9 |
|||
|- |
|||
| style="text-align:left" | Sovereign spreads -50bps |
|||
| style="text-align:right" | 1.9 |
|||
|- |
|||
| style="text-align:left" | Corporate spread +50bps |
|||
| style="text-align:right" | -0.8 |
|||
|- |
|||
| style="text-align:left" | Corporate spread -50bps |
|||
| style="text-align:right" | 0.7 |
|||
|- |
|||
| style="text-align:left" | Equities +25% |
|||
| style="text-align:right" | 1.8 |
|||
|- |
|||
| style="text-align:left" | Equities -25% |
|||
| style="text-align:right" | -2.2 |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t48" class="wikitable fintable" |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 2,163: | Line 2,097: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying Earnings before tax |
||
| style="text-align:right" | 4,229 |
| style="text-align:right" | 4,229 |
||
| style="text-align:right" | +205 |
| style="text-align:right" | +205 |
||
| Line 2,175: | Line 2,109: | ||
| style="text-align:right" | -51 |
| style="text-align:right" | -51 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Underlying Earnings |
||
| style="text-align:right" | 3,501 |
| style="text-align:right" | 3,501 |
||
| style="text-align:right" | +219 |
| style="text-align:right" | +219 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Growth vs. FY24 (at constant FX) |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | +7% |
| style="text-align:right" | +7% |
||
| Line 2,190: | Line 2,124: | ||
{{pdf page|44|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|44|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== |
=== Table of contents === |
||
* 1. Debt and Invested Assets p.31 |
* 1. Debt and Invested Assets p.31 |
||
* 2. Additional P&C disclosures p.36 |
* 2. Additional P&C disclosures p.36 |
||
| Line 2,196: | Line 2,130: | ||
{{pdf page|45|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|45|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Expanding |
=== Expanding AXA’s role in society: AXA for Progress Index{{fn ref|1|2=AXA’s Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group’s auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.}} === |
||
==== As a GLOBAL INVESTOR ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t49" class="wikitable" |
||
|- |
|||
! colspan="2" style="text-align:center" | As a GLOBAL INVESTOR |
|||
! colspan="2" style="text-align:center" | As a GLOBAL INSURER |
|||
! colspan="2" style="text-align:center" | As a COMPANY |
|||
|- |
|- |
||
! style="text-align:left" | Target |
! style="text-align:left" | Target |
||
! style="text-align:right" | 2025 Result |
! style="text-align:right" | 2025 Result |
||
|- |
|||
! style="text-align:left" | Target |
|||
| style="text-align:left" | €5bn{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}}<br/> in climate transition financing per year |
|||
! style="text-align:right" | 2025 Result |
|||
| style="text-align:right" | €6.4bn |
|||
|- |
|||
| style="text-align:left" | >€500m{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}}<br/> in community resilience financing per year |
|||
| style="text-align:right" | €1.4bn |
|||
|} |
|||
</div> |
|||
==== As a GLOBAL INSURER ==== |
|||
<div style="overflow-x:auto"> |
|||
{| id="t50" class="wikitable" |
|||
|- |
|||
! style="text-align:left" | Target |
! style="text-align:left" | Target |
||
! style="text-align:right" | 2025 Result |
! style="text-align:right" | 2025 Result |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | €6bn{{fn ref|3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}}<br/> in P&C GWP to support transition underwriting (cumulative 2024-2026) |
||
| rowspan="2" style="text-align:right" | €6.4bn |
|||
| style="text-align:left" | €6bn{{fn ref|3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}} in P&C GWP to support transition underwriting (cumulative 2024-2026) |
|||
| style="text-align:right" | €4.6bn |
| style="text-align:right" | €4.6bn |
||
| style="text-align:left" | >80,000{{fn ref|6|2=Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.}} AXA Group employees trained on climate adaptation by 2026 |
|||
| style="text-align:right" | 46,420 |
|||
|- |
|- |
||
| style="text-align:left" | >20,000{{fn ref|4|2=Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.}}<br/> climate adaptation solutions & services (cumulative 2024-2026)<br/> Target revised in 2025 |
|||
| style="text-align:left" | >€500m{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} in community resilience financing per year |
|||
| style="text-align:right" | 19,698<br/>Cumulative 2024-2025 |
|||
| style="text-align:right" | >20,000{{fn ref|4|2=Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.}} climate adaptation solutions & services (cumulative 2024-2026) Target revised in 2025 |
|||
| style="text-align:left" | 19,698 Cumulative 2024-2025 |
|||
| style="text-align:right" | Contribute to Net-Zero -50%{{fn ref|7|2=Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.}} by 2030 in absolute carbon emissions and offset of residual emissions{{fn ref|8|2=Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).}} |
|||
| style="text-align:left" | -64% Reduction against 2019 |
|||
|- |
|- |
||
| style="text-align:left" | >20m{{fn ref|5|2=Low-income to mass market segments in emerging markets and modest income segments in mature markets.}}<br/> inclusive insurance customers by 2026 |
|||
| style="text-align:left" | |
|||
| style="text-align:right" | €1.4bn |
|||
| style="text-align:left" | >20m{{fn ref|5|2=Low-income to mass market segments in emerging markets and modest income segments in mature markets.}} inclusive insurance customers by 2026 |
|||
| style="text-align:right" | 20.6m |
| style="text-align:right" | 20.6m |
||
|} |
|||
</div> |
|||
==== As a COMPANY ==== |
|||
<div style="overflow-x:auto"> |
|||
{| id="t51" class="wikitable fintable" |
|||
|- |
|||
! style="text-align:left" | Target |
|||
! class="col-m" style="text-align:right" | 2025 Result |
|||
|- |
|||
| style="text-align:left" | >80,000{{fn ref|6|2=Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.}}<br/> AXA Group employees trained on climate adaptation by 2026 |
|||
| style="text-align:right" | 46,420 |
|||
|- |
|||
| style="text-align:left" | Contribute to Net-Zero<br/> -50%{{fn ref|7|2=Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.}} by 2030<br/> in absolute carbon emissions and offset of residual emissions{{fn ref|8|2=Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).}} |
|||
| style="text-align:right" | -64%<br/>Reduction against 2019 |
|||
|- |
|||
| style="text-align:left" | 50% Percentage of AXA Group employees engaged in volunteering activities by 2026 |
| style="text-align:left" | 50% Percentage of AXA Group employees engaged in volunteering activities by 2026 |
||
| style="text-align:right" | 56% |
| style="text-align:right" | 56% |
||
| Line 2,235: | Line 2,186: | ||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
{{fn note|1=1|2= |
{{fn note|1=1|2=AXA’s Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group’s auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.}} |
||
{{fn note|1=2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} |
{{fn note|1=2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} |
||
{{fn note|1=3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}} |
{{fn note|1=3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}} |
||
| Line 2,247: | Line 2,198: | ||
{{pdf page|46|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|46|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Sustainability Performance & Ratings === |
=== Sustainability Performance & Ratings === |
||
* S&P Global: 2025 percentile: 97th{{fn ref|1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} in Dow Jones Best-in-Class Europe & World indices |
|||
* 2025 percentile: 97th{{fn ref|1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} in Dow Jones Best-in-Class Europe & World indices |
|||
* MSCI: 2025 score: AAA |
|||
* |
* 2025 score: AAA |
||
* 2025 score: B |
|||
* Morningstar Sustainalytics: 2025 ESG Risk Rating: 17.0– Low risk |
|||
* 2025 ESG Risk Rating: 17.0– Low risk |
|||
* FTSE Russell: 2025 score: 4.3/5 in FTSE4Good Index Series |
|||
* 2025 score: 4.3/5 in FTSE4Good Index Series |
|||
<div class="ed-fn-notes" style="display:none"> |
<div class="ed-fn-notes" style="display:none"> |
||
| Line 2,259: | Line 2,211: | ||
{{pdf page|47|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|47|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Scope === |
=== Scope === |
||
* France: includes insurance activities, banking activities and holding. |
* France: includes insurance activities, banking activities and holding. |
||
* Europe: includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities) and AXA Life Europe (insurance activities). |
* Europe: includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities) and AXA Life Europe (insurance activities). |
||
| Line 2,266: | Line 2,217: | ||
* Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings. |
* Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings. |
||
* AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method. |
* AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method. |
||
* * Unless otherwise specified herein, all comparative figures for going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023. Figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4, the applicable accounting standard that preceded the implementation of IFRS17/9* |
|||
* Unless otherwise specified herein, all comparative figures for going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023. Figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4, the applicable accounting standard that preceded the implementation of IFRS17/9 |
|||
{{pdf page|48|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|48|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 2,276: | Line 2,226: | ||
* CSM release: a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period |
* CSM release: a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period |
||
* Economic variance: corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force |
* Economic variance: corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force |
||
* Financial result: consists of investment income on assets backing BBA and PAA contracts as well as assets backing |
* Financial result: consists of investment income on assets backing BBA and PAA contracts as well as assets backing shareholder's equity, net of the insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow |
||
* Gross Written Premiums and Other Revenues (GWP & Other Revenues): represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities) |
* Gross Written Premiums and Other Revenues (GWP & Other Revenues): represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities) |
||
* New Business Value (NBV): the value of newly issued contracts during the current year. It consists of the sum of (i) the new business contractual service margin, (ii) the present value of the future profits of short-term newly issued contracts during the period, carried by Life entities, considering expected renewals, (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests |
* New Business Value (NBV): the value of newly issued contracts during the current year. It consists of the sum of (i) the new business contractual service margin, (ii) the present value of the future profits of short-term newly issued contracts during the period, carried by Life entities, considering expected renewals, (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests |
||
| Line 2,287: | Line 2,237: | ||
{{pdf page|49|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|49|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Thank you |
=== Thank you === |
||
* Full Year 2025 Earnings |
|||
Revision as of 21:34, 22 July 2026
| Document info | |
|---|---|
| Document ID | snjra2xp9r |
| Organization | AXA |
| Year | 2025 |
| Period | FY |
| Period label | FY25 |
| Document category | Earnings presentation |
| Document name | AXA Full Year 2025 Results Presentation |
| Publication date | 2026-02-26 |
| Language | English |
| Pages | 49 |
| Source | original URL |
| Summary | wiki page |
Full Year 2025 Earnings Presentation
IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES
- Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information. Forward-looking statements are generally identified by words and expressions such as "expects", "anticipates", "may", "plan," "target" or any variations or similar terminology of these words and expressions, or conditional verbs such as, without limitations, "would" and "could". In particular, the statements in this presentation regarding expected underlying earnings per share ("UEPS") growth for 2026 are forward-looking statements to provide one-off guidance in the context of the last year of the Group's current strategic plan. These statements in this presentation are based on Management's current views and intentions and are subject to change. Undue reliance should not be placed on forward-looking statements because, by their nature, they are subject to known and unknown risks and uncertainties, many of which are outside AXA's control, and can be affected by other factors that could cause AXA's actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements. Each forward-looking statement speaks only at the date of this presentation. Please refer to Part 5 - "Risk Factors and Risk Management" of AXA's Universal Registration Document for the year ended December 31, 2024 (the "2024 Universal Registration Document") for a description of certain important factors, risks and uncertainties that may affect AXA's business and/or results of operations. AXA specifically disclaims and undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations.
- In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures ("APMs"), used by Management in analyzing AXA's operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding AXA's results. These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group's consolidated financial statements and related notes prepared in accordance with IFRS. "Underlying earnings", UEPS ("underlying earnings per share"), "underlying return on equity", "combined ratio" and "debt gearing" are APMs as defined in ESMA's guidelines and the AMF's related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 ("AXA's 2025 Activity Report"), on the pages indicated under the heading "USE OF NON-GAAP AND ALTERNATIVE PERFORMANCE MEASURES". For further information on the above-mentioned and other non-GAAP financial measures used in this presentation, see the Glossary in AXA's 2025 Activity Report.
- AXA's Activity Report as of December 31, 2025 is available on the AXA Group website (www.axa.com).
- AXA's consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure by AXA's statutory auditors.
Table of contents
- 1. FY25 Highlights p.04
- Thomas Buberl, Group CEO
- 2. FY25 Business Performance p.09
- Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology
- 3. FY25 Financial Performance p.13
- Alban de Mailly Nesle, Group CFO
FY25 Highlights
- Thomas Buberl, Group CEO
Full Year 2025 – Excellent performance
- +6% Revenues vs. FY24
- +8% Underlying EPS vs. FY24
- 16% ROE FY25
- 224% Solvency II ratio FY25
- Delivering value for shareholders: +8% DPS1(footnote: Based on the dividend proposed by AXA’s Board of Directors on February 25, 2026 and subject to approval by the Shareholders’ Annual General Meeting to be held on April 30, 2026.) growth and €1.25bn annual share buy back2(footnote: Following AXA’s Board of Directors’ approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.)
- Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026
Executing the plan on growth, margin and efficiency
| FY24 | FY25 | |
|---|---|---|
| Underlying earnings | 8.1 | 8.4 |
+6% ( +9% excluding AXA IM)
- High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%)
- Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency
- Scaling the business: Continued investments in growth and technology
Consistent earnings growth while enhancing reserve prudence
Diversified franchise, well positioned in an attractive industry
Secular trends fueling demand across businesses
- Protection gaps and emerging corporate risks
- Demographics driving demand for private retirement and healthcare
| Segment | Share |
|---|---|
| Life | 33% |
| Health | 17% |
| Large & Specialty | 17% |
| SME & Mid-market | 16% |
| Retail | 17% |
Our right to win
- Leading brand & high customer NPS
- Strong and diversified distribution
- Technical expertise to price & underwrite risks
- Scale offering cost advantage
Laying the foundation for the next plan
- Clear tech and AI roadmap
- Driving efficiency
- Enhancing capital allocation discipline
- Building resilience
- Confidence in sustaining earnings growth
FY25 Business Performance
- Guillaume Borie
- Global Head of Finance, Strategy, Underwriting, Risk, and Technology
Strong delivery across our businesses
| Segment | Gross written premiums | Underlying earnings |
|---|---|---|
| France (27% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) |
+6% to €31bn |
+7% to €2.2bn |
| Europe (38% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) |
+6% to €43bn |
+9% to €3.5bn |
| AXA XL (17% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) |
+4% to €19bn |
+9% to €1.9bn |
| Asia, Africa & EME-LATAM (18% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) |
+13% to €20bn |
+6% to €1.5bn |
P&C – Strong margins, confidence in sustaining growth
- GWP €58bn: Retail, SME & Mid-market, AXA XL1(footnote: Includes AXA XL Re premiums of €2.6bn.) (Large & Specialty)
- 2025 / Beyond 2025:
- Retail and SME & Mid-market: Growing volumes while expanding margins (2025) | Investing to improve customer retention & expanding distribution footprint (Beyond 2025)
- AXA XL (Large & Specialty): Profitable growth with stable margins (2025) | Capitalizing on attractive growth opportunities and continued cycle management (Beyond 2025)
- Underlying earnings +9%2(footnote: Change FY25 vs. FY24 at constant FX.) to €5.9bn
- Continued progress on efficiency | Higher investment income | Data & AI to further enhance customer experience & technical excellence
L&H – Good momentum, well positioned to capture growth opportunities
- GWP: €57bn (Short-term, Long-term — shares not printed)
2025 | Beyond 2025
- Long-term business
- Accelerating net flows in Savings at attractive margins
- Capturing savings & retirement opportunity, sourcing best asset management products for our customers
- Short-term business
- Growing technical results while absorbing Mexico VAT impact
- Capitalizing on demand for health & protection while further improving our margins
- Underlying earnings +7%1(footnote: Change FY25 vs. FY24 at constant FX.) to €3.5bn
- Focus on cost reduction
- Increasing penetration of Protection riders in Savings offerings
- Leveraging AI to reduce claims leakage & improve customer outcomes in Health
FY25 Financial Performance
- Alban de Mailly Nesle
- Group CFO
P&C – Continued disciplined growth
GWP & Other Revenues
| FY24 | FY25 | Change | o/w pricing1(footnote: Price effect.) | o/w volume2(footnote: Includes exposure adjustments and mix & other effects.) | |
|---|---|---|---|---|---|
| Commercial lines | 35.8 | +4% | +2% | +2% | |
| AXA XL Reinsurance | 2.6 | +8% | +0.3% | +7% | |
| Retail lines | 19.7 | +7% | +5% | +2% | |
| Total | 56.5 | 58.0 | +5% |
- Continued pricing momentum and volume growth in Mid-market and SME
- Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance
- Growth supported by alternative capital
- Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25)
P&C – Delivering further margin expansion while enhancing reserve prudence
Combined ratio
| FY24 | FY25 | |
|---|---|---|
| Undiscounted CY loss ratio (ex Nat Cat) | 67.4% | 67.0% |
| Expense ratio | 25.0% | 24.8% |
| Nat Cat | 3.8% | 3.4% |
| Prior year reserve development | -1.6% | -1.1% |
| Discount | -3.6% | -3.5% |
| 91.0% | 90.6% |
- Better undiscounted current year loss ratio excluding Nat Cat from:
- Margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment
- Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management
- Improvement in expense ratio reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology
- Nat Cat charges below normalized load
- Lower reliance on prior year reserve development
- Taking advantage of a good year to enhance reserve prudence
P&C – Earnings growth from higher underwriting and financial result
In Euro million
| In Euro million | |
|---|---|
| FY24 | 5,510 |
| Volume growth | +292 |
| Margin improvement | +189 |
| Investment income | +435 |
| Insurance finance expenses | -235 |
| Tax | -169 |
| Affiliates, FX & other | -150 |
| FY25 | 5,872 |
+9%
- Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence
- Increase in investment income reflecting higher volumes and better reinvestment yields on fixed income assets
- Higher unwind of discount of claims reserves, in line with guidance
- Unfavorable forex impact notably due to USD depreciation vs. EUR
Change at constant FX.
Full Year 2025 Earnings
- In Euro billion
Life GWP & Other Revenues
| FY24 | FY25 | Change | |
|---|---|---|---|
| Total | 34.5 | 37.5 | +9% |
| Protection | 17.3 | +11% | |
| Unit-Linked | 9.3 | +13% | |
| Capital light G/A | 9.0 | +7% | |
| Traditional G/A | 1.9 | -7% |
Health GWP & Other Revenues
| FY24 | FY25 | Change | |
|---|---|---|---|
| Total | 17.5 | 19.0 | +5% |
| Individual | 10.5 | +6% | |
| Group | 8.5 | +4% |
Net flows: €+5.4bn
- vs. €+1.5bn in FY24
| €bn | |
|---|---|
| Protection | +4.9 |
| Health | +2.7 |
| Unit-Linked | +1.5 |
| Capital light G/A | +1.2 |
| Traditional G/A | -5.0 |
- o/w FY25 Employee Benefits1(footnote: Including both short-term and long-term Employee Benefits GWP and other revenues.) Euro 12.9 billion (+4% vs. FY24)
- Change at constant scope and FX.
Life & Health – Strong volume growth in Savings and Protection impacted by higher interest rates on discounting
PVEP
| FY24 | FY25 | Change | |
|---|---|---|---|
| Protection & Health | 31.4 | -4% | |
| Unit-Linked | 8.5 | +18% | |
| Capital-light G/A | 7.8 | -10% | |
| Traditional G/A | 1.7 | -10% | |
| Total | 50.9 | 49.4 | -2% |
NB CSM (pre-tax)
| FY24 | FY25 | Change | |
|---|---|---|---|
| NB CSM | 2.2 | 2.2 | +3% |
NBV (post-tax)
| FY24 | FY25 | Change | |
|---|---|---|---|
| NBV | 2.3 | 2.2 | stable |
NBV margin
| FY24 | FY25 | |
|---|---|---|
| NBV margin | 4.4% | 4.5% |
- PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes
- NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits
- NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France
Change at constant scope and FX.
Life & Health – Growth in new business driving Normalized CSM growth
| Value | o/w Life | o/w Health | |
|---|---|---|---|
| FY24 | 33.6 | 25.8 | 7.7 |
| New business CSM | +2.2 | ||
| Underlying return on in-force | +1.3 | ||
| CSM release | -3.0 | ||
| Economic variance | +0.6 | ||
| Operating variance | -0.3 | ||
| Affiliates, FX & other | -1.4 | ||
| FY25 | 33.0 | 25.4 | 7.6 |
- Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates
- Economic variance reflecting government spreads tightening and positive equity market returns
- Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland
- FX impact mainly from JPY and HKD depreciation
Life & Health – Strong momentum in both short-term and long-term business
In Euro million
Underlying Earnings
+7%
| FY24 | Change | FY25 | |
|---|---|---|---|
| Short-term technical margin | 415 | +60 | 479 |
| Long-term result incl. CSM release | 2,680 | +156 | 2,804 |
| Financial result | 975 | -11 | 946 |
| Tax & others | -748 | -27 | -728 |
| Underlying Earnings | 3,323 | +7% | 3,501 |
Change at constant FX.
in billions
| FY24 | FY25 | ||
|---|---|---|---|
| o/w Life | 2.6 | 2.7 | +4% vs. FY24 |
| o/w Health | 0.7 | 0.8 | +17% vs. FY24 |
- Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn)
- Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins
Growth in net income reflecting higher earnings & the gain from the sale of AXA IM
- In Euro billion
| FY24 | FY25 | Change | |
|---|---|---|---|
| Property & Casualty | 5.5 | 5.9 | +9% |
| Life & Health | 3.3 | 3.5 | +7% |
| Asset Management | 0.4 | 0.2 | -57% |
| Holdings & other | -1.2 | -1.2 | - |
| Underlying earnings | 8.1 | 8.4 | +6% |
| Non-financial flows | -0.5 | +2.1 | |
| o/w capital gains from AXA IM disposal | - | +2.2 | |
| Financial flows (incl. RCG) | +0.3 | -0.7 | |
| Net income | 7.9 | 9.8 | +26% |
- Underlying earnings
- Strong performance from insurance businesses
- Stable holding cost, expected to remain at current level in 2026
- Net Income
- Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM
- Lower financial flows reflecting unfavorable forex impact
| FY24 | FY25 | Change | |
|---|---|---|---|
| Underlying earnings per share | 3.59 | 3.86 | +8% |
- +6% from earnings growth
- +3% from capital management
- -2% from forex
- including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback
- In Euro billion
| FY24 | HY25 | FY25 | |
|---|---|---|---|
| SHE (excl. OCI) | 58.0 | 52.7 | 54.0 |
| Net OCI | -8.1 | -7.2 | -6.8 |
| Total Shareholders' equity | 49.9 | 45.5 | 47.2 |
| SHE (excl. OCI & undated subordinated debt) | 53.2 | 47.0 | 49.4 |
| Debt gearing | 20.6% | 23.4% | 22.3% |
| Underlying ROE | 15.2% | 17.5% | 16.0% |
| In Euro billion | FY24 to FY25 | HY25 to FY25 |
|---|---|---|
| Opening Shareholders' equity | 49.9 | 45.5 |
| Change in Net OCI | 1.3 | 0.4 |
| Net income for the period | 9.8 | 5.9 |
| Dividend | -4.6 | - |
| Annual share buyback | -1.2 | - |
| Anti-dilutive share buyback following the sale of AXA IM | -3.5 | -3.5 |
| Undated subordinated debt (including interest charges) | -0.3 | -1.2 |
| Forex | -3.5 | -0.1 |
| Other | -0.6 | 0.3 |
| Closing Shareholders' equity | 47.2 | 47.2 |
Higher organic cash remittance and robust cash position at Holding
- In Euro billion
| FY24 | FY25 | |
|---|---|---|
| Remittance | 7.1 | 7.5 |
| Proceeds related to in-force treaties2(footnote: 2. €0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.) | 0.6 | |
| Total | 7.7 | 7.5 |
| Remittance ratio1(footnote: 1. Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.) | 82% | 82% |
| FY24 Cash position | 4.0 |
| Net cash remittance from subsidiaries | +7.5 |
| Dividend | -4.6 |
| Annual share buyback | -1.2 |
| Anti-dilutive share buyback following the sale of AXA IM | -3.5 |
| Holding costs and interest expenses | -1.3 |
| Change in net debt | +1.6 |
| M&A and other | +3.1 |
| FY25 Cash position | 5.6 |
|---|
Solvency II at 224%
- In Euro billion
- Foreseeable dividends: €-4.8bn
- Provision for annual share buyback for 2026: €-1.25bn
| FY24 | Regulatory & model changes | Normalized capital generation | Operating variance | Economic variance & FX | Dividend & annual share buyback | Management actions, debt & other | FY25 | |
|---|---|---|---|---|---|---|---|---|
| Eligible Own Funds (EOF) | 55.9 | +0.2 | +8.8 | -0.4 | -2.1 | -6.0 | -0.1 | 56.4 |
| Solvency II ratio | 216% | +0pt | +28pts | -1pt | +4pts | -24pts | +2pts | 224% |
| Solvency Capital Requirement (SCR) | 25.9 | 0.0 | +0.6 | 0.0 | -1.2 | 0.0 | -0.2 | 25.2 |
Key sensitivities
| 224% | |
| Interest rate +50bps | +2 pts |
| Interest rate -50bps | -1 pt |
| Corporate spreads +50bps | -1 pt |
| Euro Sovereign spreads +50bps1(footnote: Sensitivity to Euro sovereign spreads assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve (applied on sovereign and quasi-sovereign exposures).) | -7 pts |
| Credit migration2(footnote: Sensitivity to credit rating migration assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches).) | -4 pts |
| Listed Equity (excl. PE & Infra) +25% | -1 pt |
| Listed Equity (excl. PE & Infra) -25% | +2 pts |
| PE & Infra +25% | +14 pts |
| PE & Infra -25% | -19 pts |
| Inflation swap curve +50bps | -5 pts |
Solvency II – impact of the end of grandfathering period and Solvency II revision
- Ratio as of 31/12/2025: 224%
- Impact of the end of grandfathering period on January 1, 2026: -10pts to 215%
- Euro 2.4 billion grandfathered debt no longer eligible as capital from January 1, 2026
- Impact of Solvency II revision to come into effect in 1Q27: +17pts1(footnote: Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.)
- No change expected in organic capital generation
- Additional capital flexibility
Conclusion
- Thomas Buberl, Group CEO
Conclusion
- Record results, at the top end of the target range while enhancing reserve prudence
- All businesses in excellent shape, delivering strong growth and profitability
- Diversified franchise, well-positioned to capture future growth opportunities
- Laying foundations for the next plan and confident in delivering sustainable earnings growth
Q&A
- Full Year 2025 Earnings
AXA Investor Relations – Keep in touch
Meet our management
- March Roadshows Europe and US
- May 5 1Q25 Activity Indicators Paris
- June 2 BNP Paribas Exane CEO Conference Paris
- June 2-4 Goldman Sachs European Financials Conference Zurich
- July 31 HY26 Earnings Release Paris
- September 21 AXA Investor Day London
Contact us
- Investor Relations +33 1 40 75 48 42 investor.relations@axa.com
Follow us
- www.axa.com
Appendices
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
Gross financial debt and maturity breakdown as of December 31st, 2025
Gross financial debt1,2
| FY24 | FY25 | Jan 1st 2026 End of the grandfathering period | |
|---|---|---|---|
| Debt gearing | 20.6% | 22.3% | - |
| Tier 1 | 4.8 | 4.6 | 3.2 |
| Tier 2 | 10.8 | 12.2 | 11.3 |
| Senior debt | 3.5 | 3.5 | 5.8 *(footnote: o/w €0.4bn redeemed in Jan 2026) |
| Total | 19.2 | 20.3 | 20.3 |
Contractual maturity breakdown
| Segment | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated |
|---|---|---|---|---|---|---|---|---|---|
| Senior debt | - | - | - | 0.5 | - | 0.9 | 1.5 | - | - |
| Tier 2 | - | - | - | - | - | 0.7 | - | 10.8 | 0.7 |
| Tier 1 | - | - | - | - | - | - | - | - | 4.6 |
| o/w Grandfathered debt | |||||||||
| Tier 1 | - | - | - | - | - | - | - | - | 1.4 |
| Tier 2 | - | - | - | - | - | 0.7 | - | 0.2 | - |
Economic maturity breakdown3(footnote: Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.)
| Segment | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated |
|---|---|---|---|---|---|---|---|---|---|
| Senior debt | - | 0.1 | - | 0.5 | - | 0.9 | 1.5 | - | - |
| Tier 2 | - | - | 2.4 | 0.1 | 2.0 | 0.7 | 6.4 | - | 0.7 |
| Tier 1 | - | - | - | - | - | - | 0.4 | 0.5 | 4.0 |
| o/w Grandfathered debt | |||||||||
| Tier 1 | - | 0.1 | - | 0.1 | - | - | 0.4 | - | 0.8 |
| Tier 2 | - | - | - | - | - | 0.7 | 0.2 | - | - |
General Account Invested Assets
FY25 Total General Account invested assets
- Duration gap at -0.4 year
- Euro 450 billion
- Fixed income
- Real estate
- Infrastructure equity
- Listed equities
- Private equity and hedge funds
- Cash
- Policy loans
| FY25 | % | |
|---|---|---|
| Fixed income | 345 | 77% |
| o/w Government bonds | 167 | 37% |
| o/w Corporate bonds and loans | 121 | 27% |
| o/w Other fixed income1(footnote: Other fixed income includes Asset Backed Securities (Euro 25 billion), Residential Loans (Euro 16 billion), Commercial & Agricultural Loans (Euro 7 billion) and Agency Pools (Euro 8 billion).) | 56 | 13% |
| Real estate | 41 | 9% |
| Infrastructure equity | 10 | 2% |
| Listed equities2(footnote: Includes hedges. Listed equities excluding hedges at Euro 14 billion.) | 10 | 2% |
| Private equity and hedge funds3(footnote: Includes Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).) | 23 | 5% |
| Cash | 19 | 4% |
| Policy loans | 2 | 0% |
| Total Insurance Invested Assets4(footnote: Please refer to the financial supplement for more details.) | 450 | 100% |
Structured and Private Credit assets
| FY25 | % of total G/A1(footnote: G/A: General Account) portfolio | Comments | |
|---|---|---|---|
| Residential Mortgages | 16 | 4% | - €6bn Dutch mortgages, NHG guaranteed - €10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV) |
| CLO & ABS | 25 | 6% | - 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA) |
| Infrastructure debt | 8 | 2% | - Skewed towards resilient industries (Telecom, Utilities, Transport) |
| CRE debt | 8 | 2% | - Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV |
| Mid-Market lending | 10 | 2% | - Strong diversification with €8m average ticket - Investments through SMAs with strict underwriting guidelines : senior secured, covenants, restrictions on asset sales and sector allocation |
| Other | 2 | 0% | |
| Total Structured and Private Credit Assets | 69 | 15% | o/w 54% participating |
Investment portfolio – Fixed Income reinvestment
FY25 Fixed Income Reinvestment
| Government bonds & related (32%) – Average rating: AA | 32% |
| Investment grade credit (40%)- Average rating: A | 40% |
| ABS/CLO/IG fund financing (21%) | 21% |
| Below investment grade credit (7%) | 7% |
FY25 Fixed Income Reinvestment Yield
| Category | Yield |
|---|---|
| Public fixed income1(footnote: Government and Corporate bonds and related.) | 3.5% |
| Private & Structured fixed income2(footnote: Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).) | 4.7% |
| Total fixed income | 3.9% |
- Euro 57 billion fixed income invested at 3.9%
- Average duration of 9 years
- Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY)
- Gradual shift from alternative total return assets to Private & Structured credit
- Full Year 2025 Earnings
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
AXA XL Insurance – Large Commercial & Specialty business
Well diversified across lines of business and geographies
| Casualty | 35% |
| Property | 29% |
| Specialty | 19% |
| Professional lines1(footnote: Including Cyber;) | 17% |
| Americas | 46% |
| Europe & APAC | 35% |
| UK & Lloyds | 19% |
Leading market positions across lines
- Top 3 globally
- Multinational Programs2(footnote: Source: McKinsey;)
- Marine3(footnote: Source: Aon, Guy Carpenter, and Global Market Insights;)
- Fine Art & Specie4(footnote: Source: Industry Research Biz (January 2026).)
Managing the cycle to deliver consistent profitability
- Profitability vs Ex-price growth (%):
- Property
- Specialty
- Casualty
- Professional lines
P&C – Focus on Reserves
| IFRS4 | IFRS17 | |||||||
|---|---|---|---|---|---|---|---|---|
| FY18 | FY19 | FY20 | FY21 | FY22 | FY22 | FY23 | FY24 | FY25 |
| 179% | 185% | 193% | 188% | 189% | 198% | 195% | 180% | 175% |
| IFRS4 | IFRS17 | |||||||
|---|---|---|---|---|---|---|---|---|
| FY18 | FY19 | FY20 | FY21 | FY22 | FY22 | FY23 | FY24 | FY25 |
| 213% | 227% | 233% | 226% | 227% | 234% | 232% | 216% | 210% |
P&C – 2026 Simplified Group Nat Cat Reinsurance Program1(footnote: Excludes local reinsurance covers;)
In Euro
Insurance segment (occurrence protection)
| Peril | Capacity | Retention |
|---|---|---|
| EU Windstorm | 4.0bn | 600m |
| Europe Flood | 2.1bn | 450m |
| Europe Earthquake | 2.1bn | 400m |
| NA Hurricane | 1.2bn | 600m2(footnote: Varying retention between MX and NA (400m MX, 600m NA);) |
| NA Earthquake | 1.2bn | 600m2(footnote: Varying retention between MX and NA (400m MX, 600m NA);) |
| Per other perils3(footnote: Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.) | 1.2bn | 400m |
Reinsurance segment (illustrative)
- Alternative Capital & Cat Bonds
- Stable retention levels maintained in 2026 as in 2025
P&C – AXA Group earnings deviation with different levels of Nat Cat cost1(footnote: Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance).) in 2026
In Euro billion (net of reinsurance)
Group underlying earnings deviation to average Nat Cat charges in 2026 net of reinsurance, post-tax
net of reinsurance, post-tax net of reinsurance, pre-tax
- More severe years: Negative deviation in ca. 40% of cases
- Less severe years: Positive deviation in ca. 60% of cases
| Return Period | Percentile | Deviation |
|---|---|---|
| 1/20y | (5th) | €-1.2bn |
| 1/10y | (10th) | €-0.8bn |
| 1/5y | (20th) | €-0.4bn |
| Median | (50th) | €+0.1bn |
| 1/5y | (80th) | €+0.5bn |
| 1/10y | (90th) | €+0.7bn |
| 1/20y | (95th) | €+0.8bn |
Average Expected Nat Cat charges net of reinsurance, pre-tax
| Year | Charges (€bn) | Estimated impact on GEP |
|---|---|---|
| 2025 | 2.6 | ca. 4.5% |
| 2026 | 2.7 | ca. 4.5% |
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
- 4. Sustainability p.44
P&C – Margin Analysis
Technical Result
*In Euro million (pre-tax)*
| FY25 | Change | |
|---|---|---|
| Current Accident Year Undiscounted Technical Margin | 2,778 | +707 |
| Gross Earned Premiums | 57,656 | +6% |
| Current Accident Year Undiscounted Combined Ratio | 95.2% | -1.0pt |
| o/w Nat Cats | 3.4% | -0.4pt |
| FY25 | Change | |
|---|---|---|
| Current Accident Year Discounting | 2,009 | +115 |
| Discounting Ratio (in Combined Ratio points) | -3.5% | +0.0pt |
| Current Accident Year Net Claims reserves | €19.0bn | |
| Duration | 4.0 years | |
| Current Accident Year Discount rate | 2.8% |
| FY25 | Change | |
|---|---|---|
| Prior Years' Reserve Development (PYD) | 622 | -341 |
| PYD ratio | -1.1% | +0.7pt |
- FY25 sensitivity to Current Accident Year discount rate changes2
- +25bps: €+0.2bn
- -25bps: €-0.2bn
Financial Result
*In Euro million (pre-tax)*
| FY25 | Change | |
|---|---|---|
| Investment Income | 3,988 | +435 |
| FY25 Average Assets | €115bn | |
| Asset book yield | 3.5% | |
| FY25 Reinvestment yield1 | 4.3% |
| FY25 | Change | |
|---|---|---|
| Insurance Finance Expenses | -1,358 | -235 |
| FY24 Reserves at locked-in rate | €71bn | |
| Liability book yield | 1.9% |
- 2026e Insurance Finance Expenses (pre-tax): ~ €-1.4bn
- Sensitivity of 2026e Insurance Finance Expenses to changes in 2025 current AY Discount
- +25bps: ~ €-50m
- -25bps: ~€+50m
| FY25 | Change | |
|---|---|---|
| Underlying Earnings before tax | 8,040 | +681 |
| Tax | -2,060 | -169 |
| Affiliates, Minority interests & Other | -108 | -10 |
| Underlying Earnings | 5,872 | +501 |
| Growth vs. FY24 (at constant FX) | +9% |
Changes versus FY24 at constant FX. 1. Reinvestment yield on fixed income assets. 2. Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.
L&H – Margin Analysis
- Includes scope impact
Technical Result
In Euro million, pre-tax
| FY25 | Change | |
|---|---|---|
| Short-term Technical Margin | 479 | +60 |
| Gross Earned Premiums | 17,416 | +10% |
| All Year Combined Ratio | 97.2% | -0.1pts |
| Incl. recapture of Laya | ||
| Long-term Technical Margin | 2,804 | +156 |
| CSM release | 2,954 | +215 |
| Technical experience | -150 | -58 |
Financial Result
In Euro million, pre-tax
| FY25 | Change | |
|---|---|---|
| Investment Income (non-VFA only) | 2,484 | -1 |
| FY25 Average Assets | €98bn | |
| Asset book yield | 2.5% | |
| FY25 Reinvestment yield1(footnote: Reinvestment yield on fixed income assets.) | 3.8% | |
| Insurance Finance Expenses (non-VFA only) | -1,538 | -9 |
| FY24 Reserves at locked-in rate | €62bn | |
| Liability book yield | 2.5% |
Life & Health FY25 CSM Key Sensitivities
(in Euro billion)
| Baseline | 33.3 |
| Interest rates +50bps | -0.8 |
| Interest rates -50bps | 0.6 |
| Sovereign spreads +50bps | -1.9 |
| Sovereign spreads -50bps | 1.9 |
| Corporate spread +50bps | -0.8 |
| Corporate spread -50bps | 0.7 |
| Equities +25% | 1.8 |
| Equities -25% | -2.2 |
| FY25 | Change | |
|---|---|---|
| Underlying Earnings before tax | 4,229 | +205 |
| Tax | -800 | 65 |
| Affiliates, Minority interests & Other | 72 | -51 |
| Underlying Earnings | 3,501 | +219 |
| Growth vs. FY24 (at constant FX) | +7% |
Table of contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
Expanding AXA’s role in society: AXA for Progress Index1(footnote: AXA’s Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group’s auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.)
As a GLOBAL INVESTOR
| Target | 2025 Result |
|---|---|
| €5bn2(footnote: Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.) in climate transition financing per year |
€6.4bn |
| >€500m2(footnote: Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.) in community resilience financing per year |
€1.4bn |
As a GLOBAL INSURER
| Target | 2025 Result |
|---|---|
| €6bn3(footnote: Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.) in P&C GWP to support transition underwriting (cumulative 2024-2026) |
€4.6bn |
| >20,0004(footnote: Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.) climate adaptation solutions & services (cumulative 2024-2026) Target revised in 2025 |
19,698 Cumulative 2024-2025 |
| >20m5(footnote: Low-income to mass market segments in emerging markets and modest income segments in mature markets.) inclusive insurance customers by 2026 |
20.6m |
As a COMPANY
| Target | 2025 Result |
|---|---|
| >80,0006(footnote: Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.) AXA Group employees trained on climate adaptation by 2026 |
46,420 |
| Contribute to Net-Zero -50%7(footnote: Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.) by 2030 in absolute carbon emissions and offset of residual emissions8(footnote: Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).) |
-64% Reduction against 2019 |
| 50% Percentage of AXA Group employees engaged in volunteering activities by 2026 | 56% |
Sustainability Performance & Ratings
- 2025 percentile: 97th1(footnote: The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.) in Dow Jones Best-in-Class Europe & World indices
- 2025 score: AAA
- 2025 score: B
- 2025 ESG Risk Rating: 17.0– Low risk
- 2025 score: 4.3/5 in FTSE4Good Index Series
Scope
- France: includes insurance activities, banking activities and holding.
- Europe: includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities) and AXA Life Europe (insurance activities).
- AXA XL: includes insurance and reinsurance activities and holding.
- Asia, Africa & EME-LATAM: includes (i) Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated, and China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S and India (Life activities disposed on March 11, 2024 and holding) businesses which are consolidated under the equity method and contribute only to NBV, PVEP, the underlying earnings and net income, (ii) Africa : Morocco (insurance activities and holding) and Nigeria (insurance activities and holding), Egypt (insurance activities and holding) which are fully consolidated, (iii) EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding) and Türkiye (insurance activities and holding) which are fully consolidated as well as Russia (Reso) (insurance activities) which consolidated under the equity method and contributes only to the net income, (iv) AXA Mediterranean Holdings.
- Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings.
- AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method.
- * Unless otherwise specified herein, all comparative figures for going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023. Figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4, the applicable accounting standard that preceded the implementation of IFRS17/9*
Glossary
- Capital-light G/A products: encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0%
- Contractual Service Margin (CSM): a component of the carrying amount of asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders
- CSM release: a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period
- Economic variance: corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force
- Financial result: consists of investment income on assets backing BBA and PAA contracts as well as assets backing shareholder's equity, net of the insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow
- Gross Written Premiums and Other Revenues (GWP & Other Revenues): represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities)
- New Business Value (NBV): the value of newly issued contracts during the current year. It consists of the sum of (i) the new business contractual service margin, (ii) the present value of the future profits of short-term newly issued contracts during the period, carried by Life entities, considering expected renewals, (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests
- New Business Contractual Service Margin (NB CSM): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided
- New Business Value margin (NBV margin): ratio of (i) NBV, representing the value of newly issued contracts during the current year, to (ii) PVEP
- Operating variance: the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes. Operating variance is net of reinsurance
- Present value of expected premiums (PVEP): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share
- Technical experience: consists the impacts on the underlying earnings if (i) the difference between the expected and incurred cash-flows of the defined period, (ii) the risk adjustment release, (iii) the changes in onerous contracts, and (iv) the other long-term elements which are mainly composed of non-attributable expenses
- Underlying return on in-force: represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance
Thank you
- Full Year 2025 Earnings